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The role of vascular endothelial growth factor (VEGF) signaling in cancer is well-
known in the context of angiogenesis but is also important in the functional regulation of 
tumor cells themselves.  Notably, autocrine VEGF signaling mediated by its co-receptors 
called neuropilins (NRPs) appears be essential for sustaining the proliferation and survival 
of cancer stem cells (CSCs), which are implicated in mediating tumor growth, progression 
and drug resistance. Therefore, the first half of this thesis focuses on the mechanism of 
VEGF-NRP-mediated support of CSCs.  Aberrant activity of the Hippo pathway effector 
YAP and TAZ are associated with breast CSCs and have been shown to confer stem cell-
like properties.  I found that VEGF-NRP2 signaling contributes to the activation of 
YAP/TAZ in various breast cancer cells, which mediates a positive feedback loop that 
promotes mammosphere formation.  VEGF-NRP2 signaling activated the GTPase Rac1, 
which inhibited the Hippo kinase LATS, which enabled the activity of YAP/TAZ. In 
complex with the transcription factor TEAD, TAZ then bound and repressed the promoter 
of the gene encoding the Rac GTPase-activating protein (Rac GAP) β2-chimaerin. By 
activating GTP hydrolysis, Rac GAPs effectively turn off Rac signaling; hence, YAP/TAZ-
mediated repression of β2-chimaerin sustained Rac1 activity in CSCs.  Depletion of β2-
chimaerin in non-CSCs increased Rac1 activity, YAP/TAZ activation and mammosphere 
formation.  Analysis of breast cancer patients revealed an inverse correlation between β2-
chimaerin and TAZ expression in tumors.  These findings highlight an unexpected role for 
β2-chimaerin in a feedforward loop of YAP/TAZ activation and the acquisition of CSC 
properties.    
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 Given that CSCs have been implicated in therapy resistance and are enriched in 
triple negative breast cancer (TNBC), which exhibits VEGF-NRP2 signaling, the second 
half of this thesis focuses on understanding the mechanism by which VEGF-NRP2 
contributes to the chemoresistance of TNBC.  I discovered that VEGF-NRP2 promote 
homologous recombination (HR) in BRCA1 wild-type TNBC cells by contributing to the 
expression and function of Rad51, an essential enzyme in the HR pathway that mediates 
efficient DNA double strand break repair.  Mechanistically, I found that VEGF-NRP2 
stimulates YAP/TAZ-dependent Rad51 expression and that Rad51 is a direct YAP/TAZ-
TEAD transcriptional target.  I also discovered that VEGF-NRP2-YAP/TAZ signaling 
contributes to the resistance of TNBC cells to chemotherapy and that Rad51 rescues the 
defects in DNA repair upon inhibition of either VEGF-NRP2 or YAP/TAZ in response to 
cisplatin.  These findings reveal novel roles for VEGF-NRP2 and YAP/TAZ in DNA repair 
and they indicate a unified mechanism involving VEGF-NRP2, YAP/TAZ and Rad51 that 
contributes to resistance to platinum chemotherapy.      
 In summary, this thesis provides novel insight into the roles of autocrine VEGF-
NRP2 signaling in breast CSC function and therapy resistance and provides rationale in 
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CHAPTER I: INTRODUCTION 
Overview 
 This thesis focuses on the mechanisms by which autocrine signaling by vascular 
endothelial growth factor (VEGF) mediated by neuropilin-2 (NRP2), a VEGF receptor, 
promotes stem-like traits, DNA repair and therapy resistance in breast cancer cells.  These 
issues are timely because VEGF is an attractive therapeutic target for breast cancer patients, 
but the available agents have demonstrated little clinical efficacy (1) and do not block the 
association between VEGF and NRPs (2).  Therefore, identifying mechanisms downstream 
of VEGF-NRP2 that contribute to the aggressive behavior of breast cancer cells has 
potentially substantial implications.   
 
Breast cancer subtypes 
 Despite research and clinical advancements in the management of patients with 
breast cancer, it continues to be the most common non-skin malignancy in women and one 
of the leading causes of cancer-related mortality in women throughout the world (3).  
Breast cancer arises from the abnormal proliferation of epithelial cells in the breast 
resulting in carcinoma.  Histological and molecular classifications of breast cancer exist 
that aid in predicting patient prognosis and response to various treatment modalities.  
Histologically, breast cancer can be divided into ductal (arising from abnormal 
proliferation of cell in ducts) or lobular (arising from abnormal proliferation cells in 
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lobules) subtypes (4).  Ductal and lobular carcinoma progresses from a benign lesion 
termed flat epithelial atypia, to a pre-cancerous lesion termed atypical hyperplasia, to 
carcinoma in situ that does not invade the basement membrane, and, finally, to invasive 
carcinoma which is malignant (4).   
 Although histological classifications of breast cancer have provided some clinical 
usefulness, determining the expression of markers for targeted therapy is critical in 
tailoring treatment strategies to the individual patient (5).  Expression of the estrogen 
receptor (ER+) and progesterone receptor (PR+) generally indicates a better outlook 
because these tumors can be treated with anti-hormonal therapy such as tamoxifen or 
aromatase inhibitors such as anastrozole or letrozole (6).  Expression of human epidermal 
growth factor receptor 2 (HER2) generally indicates a worse prognosis because these 
tumors are more aggressive in nature due to enhanced proliferative and metastatic capacity 
(6).  However, the development of HER2 blocking agents such as trastuzumab has 
improved the outcomes of patients with HER2 positive tumors (7).  Triple negative breast 
cancer (TNBC) lacks expression of the ER, PR and HER2.  These patients have the worst 
prognosis because TNBC is aggressive, poorly differentiated and effective targeted 
therapies are lacking (8).  
 In addition to assessing ER, PR and HER2 status of patients, gene expression 
profiling has revealed substantial insight into breast cancer by establishing several distinct 
subtypes that integrate hormonal profiles with neoplasm molecular cell biology (9).  
Luminal types compromise most breast cancer cases and generally have the best prognosis.  
They consist of luminal type A (40-55% of cases) (ER gene signature positive/HER2 
3 
 
negative) and luminal type B (15-20% of cases) (reduced ER gene signature with increased 
HER2).  The HER2 subtype (7-12% of cases) is ER negative and characterized by HER2 
amplification/overexpression leading to a high proliferation rate.  Basal tumors are 
negative for ER and PR and, accordingly, have a basal/myoepithelial gene signature (e.g. 
basal cytokeratin expression).  Claudin-low tumors are also ER and PR negative but exhibit 
an epithelial to mesenchymal-like gene signature.  Basal and claudin-low tumors together 
compromise TNBC, which accounts for 13-25% of cases.  Given the poor prognosis of 
TNBC patients and the lack of appropriate therapies, understanding the processes that 
contribute to its aggressive nature is of paramount importance.  This leads to a discussion 
of cancer stem cells (CSCs).  
 
Cancer stem cells 
 Breast cancer is a diverse disease composed of various cell types that differ between 
individual patients, but also within the same tumor (intratumor heterogeneity) (10).  These 
cell types exhibit distinct properties such as morphology, proliferation, degree of 
differentiation, cell-cell environment, metastatic potential and sensitivity to chemo- and 
radiation therapy (11, 12).  These observations have led to the CSC hypothesis.  CSCs are 
defined by their ability to self-renew, differentiate into multi-lineage cancer cell hierarchies 
and form a new tumor when transplanted in vivo (13).  Indeed, CSCs were identified by 
their cell surface marker expression (CD44+/highCD24-/low) following the transplantation of 
human breast cancer cells into immunocompromised mice (14).    
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 It is thought that CSCs arise following the transformation of tissue stem cells, 
which, in part, may explain their ability to divide slowly, self-renew, give rise to more 
differentiated cell types and resist genotoxic stress (10).  These properties ultimately 
facilitate their long-term survival.  However, it is important to note that there are some 
distinctions between mammary stem cells and breast CSCs.  For example, mammary stem 
cells express the cell surface marker CD24 (15), but, as mentioned above, CD24 is absent 
in breast CSCs (14).  This suggests more complex mechanisms may contribute to the 
acquisition of CSCs, which are still being elucidated.  One such mechanism may be the 
epithelial to mesenchymal transition (EMT) (16), which has been shown to promote CSC 
properties.  The seminal study reporting an association between the EMT and CSCs 
induced an EMT in human mammary epithelial cells with either TGF-β or specific 
transcription factors and observed that this changed the cells from CD44-/lowCD24+/high to 
CD44+/highCD24-/low (17).  It also promoted tumor initiating properties in vivo.    
 These observations warrant a discussion regarding the relationship between CSCs 
and different breast cancer subtypes.  TNBC, which is poorly differentiated, resists 
standard therapy, has the worst prognosis of all breast cancer subtypes exhibits the highest 
CSC burden (8, 18).  These properties may explain, in part, why patients with TNBC 
respond poorly to first-line treatments and exhibit a high rate of tumor recurrence (19).  
The next advance in improving the outlook for TNBC patients will result from a greater 
understanding of its unique biological properties that can be leveraged for targeted therapy 
intervention.  One viable option is disrupting DNA repair pathways, which next leads to a 
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discussion about the relationship between TNBC and homologous recombination (HR) 
repair.    
 
Triple negative breast cancer and homologous recombination 
 Genomic integrity can be compromised by DNA damage from exogenous (e.g. 
radiation, chemicals) and endogenous (e.g. replications errors, reactive oxygen species) 
sources, which results in instability (20).  DNA repair pathways provide a tightly controlled 
mechanism that maintains genomic integrity and resists the accumulation of deleterious 
mutations that may lead to cancer development.  Of these DNA lesions, double-strand 
breaks (DSBs) have the potential to be the most harmful (21).  The cell has evolved two 
predominant repair mechanisms that elicit highly specialized responses to DSBs: non-
homologous end joining (NHEJ) and homologous recombination (HR).  NHEJ can occur 
at any phase of the cell cycle but is predominant during G1 because it does not utilize a 
homologous template strand (22).  NHEJ has the potential for error because it processes 
and ligates DNA at the break site, which can result in insertions and deletions (22).  In 
contrast, HR occurs during the S and G2 phases of the cell cycle because a sister chromatid 
is present that is used as a template to guide repair (23).  This results in high fidelity repair 
that resists the accumulation of mutations.    
 A fraction of breast cancers (~7) are hereditary and result from the inheritance of 
susceptibility genes (9).  This is most often attributed to germline mutations in the BRCA 
1/2 genes, which are critical for HR-directed repair (24, 25).  Specifically, BRCA1 mutation 
frequency increases to up to 15% in patients with TNBC, whereas BRCA2 mutations are 
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more commonly associated with ER+ tumors (26, 27).  Accordingly, these patients have a 
high HR deficiency (HRD) score, which is a clinical measure of genomic instability (28).  
It follows that TNBC patients with germline BRCA1 mutations often develop cancer at a 
younger age (29).  However, given the defects in DNA repair resulting from non-functional 
BRCA1, clinical studies have demonstrated that these patients benefit from distinct 
treatment modalities when compared to BRCA-wild type TNBC patients.  Agents that 
induce HR, such as platinum analogues (cisplatin and carboplatin) and poly-(ADP ribose) 
polymerase (PARP) inhibitors, have proven uniquely effective for this subset of TNBC 
patients, which is a step closer to a “personalized medicine approach” (30-32).  In contrast, 
the majority of TNBCs (~85%), which are BRCA-wild type and HR proficient, are typically 
treated with taxanes and/or anthracyclines (33).  These observations have sparked intense 
interest into the underlying molecular mechanisms that govern HR and how they can be 
leveraged to sensitize DNA repair proficient tumors to agents such as platinum analogues.  
This leads to a discussion of the regulation and function of vascular endothelial growth 
factor (VEGF), which is the focus of this thesis.  
 
VEGF 
VEGF was originally isolated as an endothelial-cell specific factor that promotes 
angiogenesis and vascular permeability in several physiological and pathological contexts 
(34, 35).  Although the original factor identified is now known as VEGF-A, it belongs to 
an extensive family of mitogens that also includes VEGF-B, VEGF-C, VEGF-D and 
placental growth factor (PlGF), which differ in their VEGF receptor binding capacity, 
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tissue expression and pathophysiological functions (36).  VEGF-A, which is the focus of 
this thesis, is the classical and most heavily studied isoform and is more commonly referred 
to as VEGF.  Additional complexity of VEGF biology is through alternative splicing, 
which produces several distinct VEGF variants (VEGF121, VEGF145, VEGF148, 
VEGF165, VEGF183, VEGF189, and VEGF206) that have distinct and overlapping 
functions (36).    
Given its initial discovery in vascular and endothelial biology, VEGF regulation 
and function has dominated the angiogenesis and lymphangiogenesis fields (37).  
Specifically, studies have demonstrated that VEGF mediates the vascularization of tissues 
during development by stimulating several changes in endothelial cells including 
proliferation, sprouting, directed migration and reorganization of cell-cell junctions (38-
40).  These observations have extended beyond developmental biology because VEGF is 
now recognized as a key component of the tumor microenvironment that is essential for 
pathological angiogenesis and is also associated with poor patient prognosis (41-43).  
These observations have made VEGF and VEGF receptors attractive targets for therapeutic 
inhibition of tumor angiogenesis (44). 
However, the functions of VEGF in cancer biology extends beyond its role in 
directing angiogenesis and vascular permeability.  For example, VEGF can exert its effects 
on stromal cells such as tumor-associated fibroblasts (45) and immune cells dampening the 
anti-tumor response and contributing to tumorigenesis (46).  In addition, studies have 
demonstrated that VEGF receptors are expressed on tumor cells and that autocrine and 
paracrine VEGF signaling can impact tumor initiation and progression independently of 
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angiogenesis (42).  The focus of this thesis is the contribution of this autocrine VEGF 
signaling in sustaining the function of CSCs and contributing to DNA repair mechanisms.  
 
VEGF receptors 
 There are two types of VEGF receptors: VEGF receptor tyrosine kinases (VEGFRs) 
and neuropilins (NRPs).  The VEGFR family consists of VEGFR1 (Flt-1), VEGFR2 (Flk-
1/KDR) and VEGFR3 (Flt-4) which have distinct functions and affinity for VEGF family 
members (47).  For example, VEGFR2 exhibits a greater affinity for VEGF-A than 
VEGFR1, while VEGFR3 primarily functions as a VEGF-C and VEGF-D receptor (36, 
48).  Accordingly, VEGFR2 is recognized as the dominant receptor that mediates VEGF 
signaling in endothelial cells contributing to both developmental and pathological 
angiogenesis (47).  As mentioned above, a central theme of this thesis is that tumor cells 
express VEGF receptors and autocrine and paracrine VEGF signaling can impact cancer 
cell function independently of angiogenesis.  Several tumor types express VEGFR2, which 
can mediate VEGF signaling and is also associated with poor clinical outcomes (42, 49, 
50).     
 The observations that some tumors lack VEGFR expression but still respond to 
VEGF stimulation launched studies analyzing the contribution of other types of VEGF 
receptors to tumor biology.  Interestingly, tumor cells express NRPs in addition to VEGFRs 
(51, 52).  NRPs were initially characterized in neurodevelopment as receptors for a class 
of axon guidance factors termed semaphorins (53, 54).  Mammalian cells express two 
isoforms of NRPs (NRP1 and NRP2) that are about 40% homologous in amino acid 
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sequence but differ in their tissue expression patterns and pathophysiological functions 
(55).  NRPs primarily function as co-receptors because they possess four extracellular 
domains that contribute to ligand (VEGF and semaphorin) binding and a cytoplasmic 
domain that does not have known enzymatic activity (56-58).  NRPs do; however, contain 
a PDZ-binding domain that contributes to their association with other cell surface 
molecules.  For example, NRP association with VEGFRs (59) and other receptors such as 
α6 integrins (60) occurs through its PDZ-binding domain.  However, NRP splicing may 
differentially regulate their ability to interact with NRP interacting proteins through their 
PDZ domain (61).  Although the classical role of NRPs in endothelial cell function and 
angiogenesis are to form complexes with VEGFRs to increase their affinity for VEGF (62), 
recent studies have demonstrated that autocrine and paracrine VEGF signaling mediated 
by NRPs can impact tumor cells independently of the VEGFRs (45, 60, 63, 64).  These 
findings make NRPs attractive therapeutic targets for inhibition of VEGF signaling in 
tumor cells (65-67), and they are particularly important because bevacizumab, the most 
common anti-VEGF drug, does not block the VEGF-NRP association (2).   
 
Regulation of neuropilins in tumor cells 
 The crucial observation that this thesis builds on is that NRPs are expressed on 
tumor cells and can function in VEGF-mediated support of oncogenic processes.  The 
finding that mammary epithelial tissue exhibits very low NRP expression, but NRPs are 
highly expressed in TNBC (68) provides correlative support of their role in breast tumor 
biology.  Several mechanisms have been proposed that promote NRP expression in tumors.  
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In TNBC, the hedgehog (Hh) effector Gli1 directly binds the NRP2 promoter and induces 
its expression (68).  This promotes a positive feedback loop that sustains high NRP2 
expression in TNBC because autocrine VEGF-NRP2 signaling also induces Gli1 (68).  
Studies in prostate cancer have also provided substantial insight into NRP2 regulation and 
function.  Loss of phosphate of tensin homolog (PTEN) is a common pathologic driver of 
prostate cancer (69), which also induces NRP2 expression by a mechanism that involves 
c-jun N-terminal kinase (JNK) signaling and direct regulation of NRP2 by c-jun (66).  
Another possible mechanism that contributes to NRP2 expression in prostate cancer is 
through the analysis of COUP transcription factor II (COUP-TFII) which is associated with 
poor patient prognosis (70).  This is because COUP-TFII has been shown to directly 
stimulate NRP2 transcription in lymphatic vessel development (71).  Additionally, NRP1 
expression is induced by Sox2 in squamous cell carcinoma which contributes to tumor 
initiation and progression (72).    
 
VEGF, neuropilins and cancer stem cells 
The above observations indicate a positive causal relationship between enhanced 
NRP expression and cancer, which suggests that NRP-mediated signaling is important for 
tumor progression.  Indeed, VEGF-NRP signaling has been implicated in several aspects 
of tumor biology, especially the regulation and function of CSCs.     
As mentioned above, TNBC harbors a higher frequency of CSCs compared to other 
breast cancer subtypes (18), and VEGF and NRP2 are preferentially expressed in TNBC 
(68).  NRP2 associates with the α6β1 integrin in TNBC cells and autocrine VEGF-NRP2 
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signaling is critical for the α6β1 integrin to adhere to its extracellular matrix (ECM) ligand, 
laminin, and consequently activate focal adhesion kinase (FAK) (73).  The mechanism by 
which this is presumed to occur is through the PDZ binding domain of NRP because it has 
been shown to be important for its association with and activation of α6 integrins in 
epidermal CSCs (60).  Of note, NRP2, not NRP1, is preferentially expressed in breast CSCs 
(68).  One mechanism proposed by which VEGF-NRP2 signaling confers CSCs properties 
and promotes breast tumor initiation is through its activation of the polycomb ring finger 
oncogene BMI-1 (68), which has previously been implicated in CSC function (74, 75).  
This occurs through a FAK-Ras-Gli1 signaling mechanism (68).  The WNT-β-catenin 
pathway may also be regulated by VEGF-NRP signaling as a mechanism of CSC regulation 
(76), but more convincing evidence is needed regarding the mechanism by which these 
molecules intersect.   
CSCs have been shown to be more efficient at protecting themselves from genomic 
insults when compared to non-CSCs (77), which includes DNA damage and oxidative 
stress.  This point is worth mentioning because another interesting study demonstrated that 
the VEGF-C-NRP2 axis protects breast CSCs from oxidative stress by inducing the 
expression of superoxide dismutase 3 (Sod3) (78), which is a critical enzyme involved in 
buffering reactive oxygen species (ROS) (79).  However, the signaling mechanism by 
which VEGF-C-NRP2 regulates Sod3 was not explored.     
 Together, these studies provided a causal role of VEGF-NRP signaling in the 
regulation of CSCs.  However, a more in-depth analysis of the signaling mechanisms by 
which VEGF-NRP confers CSC properties is clearly needed.  Specifically, exploration into 
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the convergence of VEGF-NRP signaling with transcriptional regulators that promote CSC 
function would provide a more integrated mechanism by which this signaling axis 
promotes the genetic signatures that sustain the function of CSCs.  This approach is the 
foundation of this thesis and has the potential to yield substantial insight into VEGF-NRP 
biology, the regulation of CSCs and has important implications for therapy.  The leads us 
next to an overview of the regulation and function of the hippo tumor suppressor pathway.  
 
Hippo pathway: overview 
 The hippo tumor suppressor pathway was identified through mosaic screens 
designed to identify gene mutations involved in tissue overgrowth in Drosophila 
melanogaster (80-84).  The hippo pathway is conserved in mammalian cells and consists 
of a core kinase cascade in which the MST1/2 kinases (orthologues of Drosophila hippo 
kinase) associate with their binding partner Salvador (SAV1) and phosphorylate and 
activate the large tumor suppressor kinases (LATS 1/2) (orthologues of Drosophila warts 
kinase).  Other kinases including the mitogen activated protein kinase kinase kinase kinase 
4 (MAP4K4) and thousand and one amino acid kinase (TAOK) can also act in parallel to 
MST1/2 activating LATS 1/2 (85-89).   
Once activated, LATS kinases associate with another co-factor termed MOB-1 and 
directly phosphorylate and inhibit YAP and TAZ, which are the transcriptional effectors 
of the hippo pathway that are active when the pathway is “turned off.”  Yorkie is the YAP 
orthologue of Drosophila and was discovered through an analysis of warts-interacting 
proteins (90).  YAP/TAZ phosphorylation results in the creation of binding sites for 14-3-
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3 proteins, which inhibits their ability to regulate transcription because it results in their 
cytoplasmic retention and degradation (91, 92).  YAP/TAZ do not directly bind DNA 
because they do not contain DNA binding domains.  The primary transcription factor that 
they associate with to control gene expression are the mammalian TEA domain (TEAD) 
1-4 family (orthologue of Drosophila Scaloped), which, together, regulates the expression 
numerous genes that control cell survival, proliferation and the acquisition of stem cell 
properties (93-95).     
 Since the discovery of the core hippo pathway, its characterization has provided 
substantial insight into developmental biology, organ growth control and tissue 
homeostasis (96).  However, it is now known that the hippo pathway kinase cascade can 
be activated or inhibited by the intersection of numerous other molecular components.  
Merlin, the protein product of the neurofibromatosis type 2 (NF2) gene, is a potent activator 
of the hippo pathway.  Merlin is an erzin, radixin, moesin (ERM)-related protein that 
functions as a scaffold at the membrane- cytoskeleton interface activating the MST-LATS 
kinase cascade (97).  There is also evidence that Merlin can directly activate LATS kinases 
(98, 99).  These observations highlight an important point relating cellular architecture and 
actin dynamics in hippo pathway regulation because mechanical tension is a strong 
activator of YAP/TAZ (100).  Rho family GTPases have taken center stage in this regard 
because of their role in actin polymerization and stress fiber formation (101).  What has 
been reported is that mechanical cues mediated by Rho GTPases inhibits LATS kinases 
and thereby facilitates YAP/TAZ nuclear localization and activation (89, 102, 103).    
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 An area that is still emerging in hippo biology is the contribution of soluble factors 
and upstream receptor signaling in the regulation of hippo pathway components.  One 
example of ligand-receptor signaling that has been explored rigorously is the role of ligand-
G protein-coupled receptor (GPCR) signaling, which has been implicated in YAP/TAZ 
regulation by a mechanism involving Rho GTPases (103).  Alternative WNT signaling is 
another example of a ligand-GPCR-Rho mechanism that regulates the transcriptional 
activity of YAP/TAZ (102).  Mechanisms have been proposed that occur independently of 
GPCRs such as transforming growth factor beta (TGF-β) (104-106) and bone morphogenic 
protein (BMP) signaling mechanisms (107).  Nonetheless, much remains to be learned 
regarding the broad landscape of ligand-receptor signaling and the intersection of different 
molecular pathways in hippo pathway regulation.  This need is heightened because 
dysregulation of these and other pathways have been implicated in tumor initiation and 
progression.  
 YAP/TAZ are widely recognized as critical oncogenes involved in many of the 
hallmarks of cancer (108), which meshes with previous studies in Drosophila 
demonstrating that Yorkie promotes cell proliferation and resists apoptosis (90).  A recent 
study reported dysregulation of hippo pathway components in a comprehensive analysis of 
over 9000 tumor samples, which includes squamous cell carcinoma, brain, gastrointestinal 
and other malignancies (109).  Breast cancer is one of the most heavily studied tumor types 
that exhibits hyper-activation of YAP/TAZ, which is associated with CSC properties, high-
grade, TNBCs and poor patient prognosis (110, 111).  As mentioned above, CSCs exhibit 
properties of an EMT (16), which is significant because TAZ can induce an EMT in 
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mammary epithelial cells  (112).  Moreover, YAP/TAZ are critical for transcriptional 
addiction and therapy resistance in TNBC (113).  Although they are attractive 
pharmacological targets, therapeutic inhibition of YAP/TAZ has been a challenge (114).  
Additionally, upstream signaling mechanisms that disrupt hippo signaling and contribute 
to enhanced YAP/TAZ activity in different tumor types are still being elucidated.  Further 
investigation into these processes has the potential to uncover previously unknown 
regulators of the hippo pathway and may identify novel therapeutic targets that disrupt 
YAP/TAZ activity.  
 
Rationale for thesis work 
 Although YAP/TAZ are crucial breast CSC oncogenes, the upstream signaling 
mechanisms that disrupt hippo signaling and contribute to their hyper-activation have 
remained elusive.  Given the available evidence mentioned above, albeit limited, linking 
autocrine VEGF-NRP2 signaling and breast tumor initiation, I initiated the work in Chapter 
II of my thesis by pursuing the hypothesis that the mechanism by which the VEGF-NRP2 
signaling axis confers CSC properties in breast cancer cells is through downstream 
YAP/TAZ activation.  The results I obtained validated my hypothesis by uncovering a 
previously unknown positive feedback circuit that sustains enhanced YAP/TAZ activity 
involving the Rho family GTPase Rac1, and consequent repression of a Rac1 regulatory 
protein by YAP/TAZ-mediated transcriptional regulation.  
 In Chapter III of my thesis, I extended my conclusions from Chapter II that 
YAP/TAZ are downstream effectors of VEGF-NRP2 signaling by analyzing the 
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implications of this molecular association to DNA repair pathways and therapy resistance.  
This is because, although VEGF-NRP signaling and YAP/TAZ have been independently 
implicated in resistance to chemo- and radiotherapy in several tumor types, much remains 
to learned regarding the mechanisms by which they promote therapy resistance.  Moreover, 
the contribution of both VEGF-NRP signaling and YAP/TAZ to DNA repair pathways has 
not been explored, which is ripe for investigation because many cancer therapies induce 
DNA damage.  My hypothesis that VEGF-NRP2-YAP/TAZ signaling promotes resistance 
to DNA damaging agents is timely because recent clinical evidence has demonstrated the 
efficacy of specific treatment modalities for TNBC patients with deficiency in HR-directed 
repair.  These findings have heightened the need for a better understanding of the 
mechanisms that contribute to efficient DNA repair in subgroups of TNBC patients to 
increase their response to HR-inducing therapies.  In pursuit of this mechanism, I 
discovered that VEGF-NRP2-YAP/TAZ signaling promotes HR and therapy resistance in 
TNBC cells by directly regulating the expression of Rad51, which is a central enzyme in 
HR-directed repair.  
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Vascular endothelial growth factor (VEGF) was originally characterized as a 
protein that promotes endothelial growth (34) and increases vascular permeability (35).  
For these and other reasons, it was presumed that the role of VEGF in cancer was limited 
to angiogenesis (34, 41, 44, 115).  It is evident now, however, that there are angiogenesis-
independent functions of VEGF in cancer that are mediated by specific receptors.  Tumor 
cells express VEGF receptor tyrosine kinases (VEGFR1 and VEGFR2) and neuropilins 
(NRPs), another family of VEGF receptors.  NRP1 and NRP2 were identified initially as 
neuronal receptors for semaphorins, which are axon guidance factors that function 
primarily in the developing nervous system (116).  The finding that NRPs can also function 
as VEGF receptors and that they are expressed on endothelial and tumor cells launched 
studies aimed at understanding their contribution to angiogenesis and tumor biology (52).  
NRPs have the ability to interact with and modulate the function of VEGFR1 and VEGFR2, 
as well as other receptors (62, 117, 118).  There is also evidence that NRPs are valid targets 
for therapeutic inhibition of angiogenesis and cancer (65-67, 119).   
A surge of evidence has implicated autocrine VEGF signaling mediated by NRPs 
in the function of cancer stem cells (CSCs), a sub-population of cells that function in tumor 
initiation, the differentiation of multi-lineage cancer cell hierarchies, therapy resistance and 
metastasis (14, 42, 66, 120-124).  These observations have led to intense investigation into 
the mechanisms by which VEGF sustains CSCs and how these processes can be exploited 
therapeutically.  Previously, we reported that NRP2 is highly expressed in breast CSCs and 
that VEGF-NRP2 signaling contributes to breast tumor initiation (68).  A key issue that 
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emerges from these findings is the mechanism by which VEGF-NRP2 signaling 
contributes to the function of CSCs.  In pursuit of this issue, we were intrigued by reports 
that the Hippo pathway transducer TAZ confers stem cell properties and contributes to 
breast tumorigenesis, especially in high-grade tumors, which are distinguished by high 
NRP2 expression and VEGF-NRP2 signaling activity (68).  Moreover, TAZ expression in 
breast cancer correlates with tumor grade (111) and high-grade tumors harbor a higher 
frequency of CSCs than do lower grade tumors (18).  Mechanistic studies have shown that 
TAZ can induce an epithelial to mesenchymal transition (EMT) in mammary epithelial 
cells (112), a process that can increase stem cell properties (125).  Moreover, TAZ is 
necessary for the self-renewal of CSCs (111).  In contrast, the role of YAP in breast cancer 
is less clear and its expression does not correlate with clinical outcome (110).   
The Hippo pathway consists of core kinases and regulatory molecules that facilitate 
TAZ phosphorylation, cytoplasmic retention and inactivation (91, 126, 127).  For this 
reason, identifying upstream receptors that disrupt Hippo signaling and, consequently, 
enhance TAZ activity is critical for understanding how these effectors contribute to the 
function of CSCs.  In this study, we discovered that VEGF-NRP2 signaling contributes to 
increased TAZ activity by a Rac1-dependent, feed-forward mechanism.       
 
Results 
VEGF-NRP2 Signaling Contributes to TAZ Activation:  Initially, we assessed the 
contribution of VEGF-NRP2 signaling to TAZ activation.  For this purpose, we used an 
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inducible system to transform MCF10A cells with Src, which generates a population of 
CD44high/CD24low cells with CSC properties (128).  This population is actually comprised 
of distinct epithelial (EPTH) and mesenchymal (MES) populations that differ in TAZ 
activity and tumor initiating potential.  The MES population has enhanced TAZ activity, 
self-renewal potential and tumor initiating capability compared to the EPTH population 
(129).  Importantly, MES cells express increased levels of VEGF and NRP2 compared to 
EPTH cells and are dependent on VEGF-NRP2 signaling for self-renewal (130).  
Expression of either NRP2 (Figure 2.1A) or VEGF (Figure 2.1B) was diminished in MES 
cells using shRNAs, which resulted in decreased TAZ abundance compared to control cells 
as assessed by immunoblotting (Figures 2.1, A and B).  As reported previously, TAZ 
abundance is an indicator of its activation status (102, 131), as well as its nuclear 
localization.  For this latter reason, we compared TAZ localization in control cells to 
VEGF- and NRP2-depleted cells by immunofluorescence (Figure 2.1C; 2.9A).  TAZ is 
localized primarily in the nucleus in control MES cells (Figure 2.1C; 2.9A).  In contrast, 
little, if any, TAZ was detected in VEGF- and NRP2-depleted cells, which is consistent 
with our immunoblotting data (Figures 2.1, A and B).  The TAZ that was detected in 
VEGF-depleted cells is localized in the cytoplasm (Figure 2.1C; 2.9A).            
Depletion of NRP2 in MES cells also reduced the mRNA expression of the TAZ 
target genes CTGF and CYR61 (Figure 2.1D).  To substantiate the data obtained with 
shRNAs, we treated MES cells with a function-blocking NRP2 antibody (65) and observed 
a concentration -dependent decrease in TAZ abundance (Figure 2.1E).  Although similar 
results were obtained with YAP (Figure 2.9B-C), we focused subsequent experiments on 
21 
 
TAZ because convincing data correlating YAP expression and clinical parameters in breast 
cancer are lacking (110).       
We extended this analysis to MDA-MB-231 cells because they exhibit 
mesenchymal properties and highly express VEGF and NRP2 (130).  Similar to MES cells, 
NRP2 depletion reduced the abundance of TAZ, as well as TAZ target genes, (Figures 2.1, 
F and G) suggesting that NRP2 affects TAZ-mediated transcription.  TAZ regulates gene 
expression by associating with the TEAD family of transcription factors (95), which infers 
that NRP2 should affect TEAD transcriptional activity.  Indeed, the activity of a TEAD 
luciferase reporter was reduced significantly in MDA-MB-231 cells with diminished NRP2 
expression compared to control cells (Figure 2.1H).   
Rac1 Facilitates VEGF-NRP2–mediated Activation of TAZ:  To investigate the 
mechanism by which VEGF-NRP2 signaling activates TAZ, we focused on Rac1 for 
several reasons.  This GTPase is a major effector of NRP/plexin signaling in neurons (132, 
133) and it has been implicated in VEGF signaling in endothelial cells (134, 135).  
Moreover, Rac1 has also been implicated in TAZ activation (102, 136-138).  We observed 
that depleting VEGF expression or treating MES cells with the NRP2 function-blocking 
antibody resulted in a substantial decrease in Rac1 activity (Figures 2.2, A and B).  Similar 
results were obtained with MDA-MB-231 cells (Figure 2.2C).  Conversely, stimulating 
MDA-MB-231 cells with VEGF resulted in an increase in Rac1 activity (Figure 2.2D).      
An important issue is whether VEGFRs contribute to Rac1 activation in breast 
cancer cells.  Treatment of MDA-MB-231 cells with the VEGFR inhibitors pazopanib and 
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subitinib in the presence of VEGF did not decrease Rac1 activity compared to VEGF alone 
(Figure 2.10), suggesting that VEGF-NRP2 activation of Rac1 is VEGFR-independent.  
This result is not surprising because we reported previously that MDA-MB-231 and other 
breast cancer cell lines express very low levels of VEGFRs (139).  In contrast, VEGF-
NRP2–mediated Rac1 activation appears to be focal adhesion kinase (FAK)-dependent, 
because the FAK inhibitor FAK14 significantly decreased Rac1 activity in MES cells 
(Figure 2.2E).  This result is consistent with previous findings that FAK is a downstream 
effector of VEGF-NRP2 signaling (68), and it has been implicated in Rac1 activation (140-
142), as well as Hippo pathway regulation (143, 144).       
The results described above prompted us to evaluate whether VEGF-NRP2 signals 
through Rac1 to promote TAZ activation.  Based on our finding that depletion of NRP2 in 
MDA-MB-231 cells decreased the expression of TAZ target genes (Figure 2.2G), we 
found that expression of a constitutively active V12 Rac1 in these cells rescued their 
expression (Figure 2.2F).  This result provides evidence that the VEGF-NRP2-Rac1 axis 
contributes to TAZ activation.  Subsequently, we assessed the role of Rac1 inhibition on 
mammosphere formation in MES cells and observed decreased mammosphere formation 
upon treatment with the Rac inhibitors EHT1864 and NSC23766 (Figure 2.2G).    
We next sought to investigate the mechanism by which VEGF-NRP2-mediated 
regulation of Rac1 contributes to TAZ activation.  We focused on the LATS tumor 
suppressor kinases because they phosphorylate TAZ directly at the Ser89 position and 
promote its cytoplasmic retention and degradation when phosphorylated and activated on 
their hydrophobic motifs (Thr1079 in LATS1, Thr1041 in LATS2)  (112, 145, 146).  
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Moreover, LATS can be regulated by Rac1 (102, 136, 137).  Treatment of MES cells with 
the Rac inhibitor EHT1864 resulted in a concentration-dependent increase in the 
abundance of phosphorylated Ser89 (pSer89) TAZ and a concomitant decrease in TAZ 
abundance (Figure 2.3A).  It also increased the abundance of pThr1079 LATS1 and 
decreased TAZ abundance as early as 15 minutes after treatment, and this pattern persisted 
for up to 6 hours (Figure 2.3B).  Expression of dominant-negative N17 Rac1 also 
decreased TAZ abundance in MES cells (Figure 2.3C).  Similar results were obtained with 
the NRP2 function-blocking antibody (Figure 2.3D).  NRP2 knockdown in MDA-MB-231 
cells also increased the abundance of pSer89 TAZ and pThr1079 LATS1 and decreased the 
abundance of TAZ (Figures 2.3, E and F).  NRP2 depletion also increased LATS-
mediated YAP phosphorylation (pSer127) (Figure 2.9B).  LATS knockdown rescued TAZ 
abundance in NRP2 depleted MDA-MB-231 cells, which shows that VEGF-NRP2-Rac1 
regulation of TAZ is LATS-dependent (Figure 2.11A).     
Given the importance of TAZ in promoting CSC properties (111), we hypothesized 
that VEGF-NRP2-Rac1-mediated LATS inhibition is a critical upstream regulator of TAZ-
mediated mammosphere formation.  Depletion of NRP2 in MDA-MB-231 cells 
significantly reduced mammosphere formation, which was partially rescued by expression 
of wild-type TAZ (Figure 2.3G; 2.12).  Expression of S89A TAZ, which is resistant to 
LATS-mediated phosphorylation at that site, rescued mammosphere formation 
significantly more than did expression of wild-type TAZ (Figure 2.3G; 2.12).  Similar 
results were obtained by VEGF depletion in MES cells (Figure 2.3H).  These results 
indicate that the wild-type TAZ ectopically expressed is subject to regulation by upstream 
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VEGF-NRP2 signaling, but that the S89A TAZ mutant is not.  Together, these data provide 
functional evidence that VEGF-NRP2-Rac1 promotes a TAZ-dependent stem-like 
phenotype through inhibition of LATS-mediated phosphorylation of TAZ at Ser89.   
To gain insight into the mechanism by which VEGF-NRP2-Rac1 signaling inhibits 
LATS activity, we postulated that this signaling regulates Merlin, the protein product of 
the Neurofibromatosis type 2 (NF2) gene, because phosphorylation of Merlin on Ser518 by 
p21-activated kinase (PAK) is inhibitory (147-149).  Moreover, Merlin phosphorylation 
inhibits LATS phosphorylation (97).  These findings are relevant because PAK is a Rac-
activated kinase (150).  Following these observations, we found that either Rac inhibition 
or NRP2 depletion in MES cells reduced the abundance of Ser518 -phosphorylated Merlin 
(Figure 2.11B and C).         
VEGF-NRP2 Signaling Represses the Rac GAP β2-chimaerin:  Rac1 cycles from 
GTP-bound active states to GDP-bound inactive states, which, in large part, is regulated 
by the expression of guanine nucleotide exchange factors (GEFs) and GAPs.  Therefore, 
we profiled the expression of known Rac GEFs and GAPs in EPTH and MES cells (Table 
2.1).  Notably, we observed that the expression of the Rac GAP β2-chimaerin was markedly 
reduced in MES cells compared to EPTH cells (Table 2.1), which we verified by 
immunoblotting (Figure 2.4A).  β2-chimaerin is a Rac-specific GAP that has been 
implicated as a tumor suppressor in breast cancer (151-155).  Given that β2-chimaerin 
abundance is reduced in MES cells and these cells highly express VEGF and NRP2 (130), 
we assessed whether VEGF-NRP2 signaling repressed β2-chimaerin expression.  Indeed, 
we observed that NRP2 depletion increased β2-chimaerin mRNA and protein expression 
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in MES cells (Figures 2.4, B and C). Treatment of MES cells with the NRP2 function-
blocking antibody also increased β2-Chimaerin abundance (Figure 2.4D).  These 
observations provide evidence that VEGF-NRP2 signaling represses β2-chimaerin 
expression.    
TAZ Activates Rac1 by Repressing β2-chimaerin through a TEAD-Dependent 
Mechanism:  Based on our observation that VEGF-NRP2 signaling activates TAZ and 
represses β2-chimaerin, we assessed the possibility that TAZ represses β2-chimaerin.  This 
possibility is supported by studies demonstrating that TAZ can function in transcriptional 
repression (156, 157).  Depletion of TAZ in MES cells caused an increase in β2-chimaerin 
mRNA and protein expression and a consequent decrease in Rac1 activity (Figures 2.5, A 
to C).  TAZ knockdown in MDA-MB-435 cells (Figure 2.5D) and MDA-MB-231 cells 
(Figure 2.5E) also increased β2-chimaerin mRNA expression.  Conversely, TAZ 
overexpression repressed β2-chimaerin mRNA expression in MDA-MB-231 cells (Figure 
2.5F).  Given our observations that Rac1 activates TAZ (Figure 2.3) and that TAZ 
represses β2-chimaerin expression, we inhibited Rac1 in MES cells using EHT1864 and 
observed an increase in the expression of β2-chimaerin mRNA (Figure 2.5G).  These 
results provide evidence that VEGF-NRP2-Rac1-mediated TAZ activation maintains 
elevated Rac1 activity by repressing β2-chimaerin in a positive feedback loop.    
TAZ-mediated transcriptional repression is dependent on the TEAD1-4 family of 
transcription factors (156, 157).  TEAD4, in particular, is expressed at relatively high levels 
in breast cancer, especially triple negative breast cancer (158, 159).  Given this information, 
we initially searched the encyclopedia of DNA elements (ENCODE) for TEAD4 ChIP-seq 
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datasets and found 4 cell types (h1-human embryonic stem cells, HCT116 colon cancer 
cells, Ishikawa endometrial adenocarcinoma cells and SK-N-SH neuroblastoma cells) 
where TEAD4 bound to the promoter region of the β2-chimaerin gene (Figure 2.6A).  
Specifically, a conserved peak was observed near position 29229000 (chr7) in all of the 
cell types.  These findings are significant because they demonstrate direct binding of 
TEAD4 to the β2-chimaerin promoter.  Also, h1-hESCs, HCT116, Ishikawa and SK-N-SH 
cells have enhanced TAZ/TEAD activity (160, 161).  To validate the ENCODE data in our 
model system, we performed ChIP in MES cells using antibodies specific for TEAD4 and 
TAZ.  The results verify that TEAD4 and TAZ are recruited to the genomic region in the 
β2-chimaerin promoter identified in ENCODE (Figure 2.6B).  Based on these data, we 
depleted TEAD1/3/4 expression in MES cells and observed an increase in β2-chimaerin 
mRNA and protein expression (Figures 2.6, C and D) and a decrease in Rac1 activity 
(Figure 2.6E), consistent with our TAZ knockdown results (Figures 2.5, A to C).  
Similarly, expression of dominant-negative TEAD4 in MDA-MB-231 cells increased β2-
chimaerin mRNA expression (Figure 2.6F).       
β2-chimaerin Repression Contributes to Enhanced TAZ Activity:  An important 
issue that arises from the data thus far is whether β2-chimaerin repression has a causal role 
in TAZ activation.  Expression of β2-chimaerin in MDA-MB-231 cells decreased Rac1 
activity, as well as the abundance of TAZ itself (Figure 2.7A) and TAZ target genes 
(Figure 2.7B).  Conversely, β2-chimaerin knockdown in EPTH cells increased Rac1 
activity, TAZ abundance (Figure 2.7C) and TAZ target genes (Figure 2.7D).  Notably, 
β2-chimaerin-depleted EPTH cells exhibited increased mammosphere formation compared 
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to control EPTH cells (Figure 2.7E).  Expression of β2-chimaerin also reduced TAZ-
mediated, but not S89A TAZ-mediated, mammosphere formation in MDA-MB-231 cells 
(Figure 2.7F), providing further evidence that Rac1 inhibition of LATS contributes to TAZ 
activation and CSC properties.  
These in vitro data indicating an inverse causal relationship between β2-chimaerin 
and TAZ and a positive causal relationship between VEGF-NRP2 and TAZ were 
substantiated by analysis of their expression in invasive breast carcinomas in The Cancer 
Genome Atlas (TCGA) database obtained from cBioPortal (162, 163) (Figure 2.7G).  
Indeed, the expression of TAZ and β2-chimaerin were inversely correlated.  In contrast, 
the expression of TAZ correlated with that of VEGF and NRP2.  An inverse correlation 
between TAZ and β2-chimaerin was also detected in glioblastoma and colorectal 
adenocarcinoma samples in the TCGA.  These findings are significant because both 
glioblastoma and colon cancer exhibit enhanced TAZ activity (160, 164, 165).  Lastly, 
TAZ and β2-chimaerin exhibited an inverse correlation in the cancer cell line encyclopedia 
obtained from cBioPortal (967 cell lines) (Figure 2.7G), which provides further evidence 
of a repressive role (162, 163).        
Our data indicate that TAZ-mediated repression of β2-chimaerin is associated with 
a mesenchymal phenotype.  To substantiate this conclusion, we analyzed a microarray 
(GSE48204) that utilized TGF-β-treated NMuMG mammary epithelial cells                                                                                                                                                                                       
to induce an EMT (166).  In support of our conclusion, we found that the EMT reduced 
β2-chimaerin expression and increased expression of VEGF and NRP2, as well as TAZ 
target genes (Figure 2.13).  We also used cBioPortal to stratify breast cancer patients in 
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the TCGA database based on their expression of the estrogen receptor (ER), which is 
associated with an epithelial phenotype.  Comparison of β2-chimaerin expression in the 
estrogen receptor-positive (ER+) and ER- subgroups revealed that ER- patients have lower 
expression of β2-chimaerin compared to ER+ patients (Figure 2.7H). 
 
Discussion 
The results of this study establish a causal role for VEGF-NRP2 signaling in 
sustaining the activation of TAZ, a critical effector molecule of the Hippo pathway that 
contributes to breast tumorigenesis and is associated with aggressive, high-grade tumors.  
An essential component of this mechanism is the repression of β2-chimaerin, a Rac GAP, 
by TAZ and the consequent activation of Rac1 resulting in a positive feedback loop driven 
by VEGF-NRP2 signaling that sustains TAZ activation (Figure 8).  These findings 
increase our understanding of autocrine VEGF signaling in tumor cells and they 
substantiate the importance of Rac in the biology of CSCs and TAZ regulation.       
Our conclusion that repression of β2-chimaerin contributes to TAZ activation and 
self-renewal indicates that this Rac GAP is an important gatekeeper that impedes the 
acquisition of stem cell properties.  Based on the hypothesis that breast CSCs are de-
differentiated and exhibit features of an EMT (125), this conclusion infers that repression 
of β2-chimaerin is a consequence of the EMT and that its expression is associated with an 
epithelial phenotype.  Indeed, we uncovered that β2-chimaerin is repressed by the TGF-β-
induced EMT of mammary epithelial cells.  Importantly, we also demonstrated that ER+ 
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patients have higher β2-chimaerin expression compared to ER- patients.  These 
observations contrast with the report that β2-chimaerin reduces E-cadherin levels in an in 
vitro overexpression system (154).  Interestingly, however, this report also demonstrated 
that low expression of β2-chimaerin is associated with reduced relapse-free survival of 
breast cancer patients, which supports our findings.     
Our results need to be discussed in the context of the report that NRP2 binds β2-
chimaerin directly, and that Semaphorin3F-NRP2 signaling reduces this association to 
activate β2-chimaerin and regulate axonal pruning in the hippocampus (133).  Although 
β2-chimaerin and NRP2 exhibit an inverse expression pattern in breast cancer, we tested 
the hypothesis that residual β2-chimaerin may be sequestered and inactivated by NRP2 as 
a mechanism of Rac1 regulation.  However, we were unable to co-immunopurify NRP2 
with β2-chimaerin.  This is not definitive, but it does suggest NRP2 regulation of β2-
chimaerin differs in breast cancer cells and neurons.  This difference may reflect the fact 
that different ligands (Semaphorin3F and VEGF) engage NRP2 in these cells types.  It is 
also worth mentioning that we previously demonstrated that Semaphorin3A and VEGF 
compete for NRP binding in breast cancer cells, and that these two ligands have opposite 
effects on the behavior of these cells (167).  Nonetheless, the existing data highlight an 
important causal effect of NRP2 on β2-chimaerin that is executed by distinct mechanisms.           
A major conclusion of this study is that VEGF-NRP2 signaling contributes to TAZ 
activation by a Rac1-dependent mechanism.  This role for Rac1 differs from its more 
established role in regulating cell invasion and migration in cancer, but it is consistent with 
other reports implicating Rac1 in the function of CSCs (168-170), as well as in YAP/TAZ 
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activation (102, 136-138).  Our results on the ability of VEGF-NRP2 signaling to inhibit 
LATS by a Rac1-dependent mechanism support these observations and they identify a 
novel ligand-receptor interaction that can mediate this regulation.  Furthermore, our data 
suggest that the ability of Rac1 to inhibit LATS is mediated by its regulation of Merlin, 
which is an important organizer of the membrane-cytoskeleton interface (89, 97-99, 147-
149).  Although we are not ruling out the possibility that VEGF-NRP2 signaling may 
activate RhoA, which has also been implicated in YAP/TAZ activation (89, 100, 102, 103, 
136), we focused our attention on Rac1 because β2-chimaerin is Rac-specific and does not 
have GAP activity against Rho (151, 152).      
Although many studies have implicated autocrine VEGF signaling in the function 
of CSCs (42), its ability to contribute to Hippo-TAZ regulation provides a new dimension 
to our understanding of VEGF biology.  While this manuscript was in review, however, it 
was reported that VEGF-VEGFR2 signaling contributes to YAP/TAZ activation during 
developmental angiogenesis (171).  Our data support the role of VEGF in promoting 
YAP/TAZ activation, but the mechanism used by breast cancer cells is distinct because it 
appears to be dependent on VEGF-NRP2 activation of FAK-Rac1 but independent of 
VEGFR.  Moreover, our findings reveal a pivotal role for β2-chimaerin as a repressive 
intermediary between VEGF-NRP2 and TAZ activation.  They also reinforce the 
hypothesis that targeting VEGF-NRP signaling is a viable therapeutic strategy for tumor 




Materials and Methods 
Reagents and Antibodies  
EHT1864 was purchased from Tocris, NSC23766 was purchased from Selleckchem, 
FAK14 was purchased from Sigma, Sunitinib and Pazopanib were purchased from LC 
Laboratories, human VEGFA165 was purchased from R&D Systems and the function-
blocking Neuropilin-2 antibody was provided by Genentech (65).  Immunoblotting 
antibodies were acquired as follows: Actin (A2066, Sigma), TAZ (560235, BD 
Biosciences), YAP/TAZ (8418S, Cell Signaling Technologies), pS89 TAZ (sc-17610, 
Santa Cruz Biotechnology), pS127 YAP (4911A, Cell Signaling Technologies),  
Neuropilin-2 (sc-7242, Santa Cruz Biotechnology), β2-chimaerin (CHN2) (HPA018989, 
Sigma), pT1079 LATS1 (8654S, Cell Signaling Technologies), LATS1 (9153S, Cell 
Signaling Technologies), VEGF (sc-152, Santa Cruz Biotechnology), Rac1 (610650, BD 
Biosciences), Pan-TEAD (13295S, Cell Signaling Technologies), pS518 Merlin (9163S, 
Cell Signaling Technologies), Merlin (6995S, Cell Signaling Technologies), HA-Tag 
(3724S, Cell Signaling Technologies), GST (sc-138, Santa Cruz Biotechnology) and Myc-
Tag (2278S, Cell Signaling Technologies).  
Constructs 
The following lentiviral shRNA vectors were used:  VEGF (TRCN0000003343, 
TRCN0000003344, TRCN0000003345), Neuropilin-2 (TRCN0000063309, 
TRCN0000063312, TRCN0000063310), β2-chimaerin (provided by Dr. Alex Kolodkin, 
Johns Hopkins Medical Institute (133)) and TEAD 1/3/4 (provided by Dr. Junhao Mao, 
University of Massachusetts Medical School (160)).  Retroviral shTAZ vectors were used 
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as previously described (129).  Stable shRNA expression was accomplished by selecting 
cells in 2 µg/mL puromycin for 2 to 4 days.  Myc-tagged (6X) β2-chimaerin was provided 
by Dr. Alex Kolodkin, Johns Hopkins Medical Institute (133), Myc-tagged dominant 
negative TEAD4 was provided by Dr. Junhao Mao, University of Massachusetts Medical 
School, dominant negative Rac1 (N17Rac1) and constitutively active Rac1 (V12Rac1) 
were described previously (124).  Human TAZ was cloned into pcDNA3.1 vector and site-
directed mutagenesis was performed to generate TAZ S89A (fig. S6).       
Cell Culture    
ER-SRC transformed MCF10A cells were provided by Dr. Kevin Struhl (Harvard Medical 
School).  To generate puromycin sensitive MCF10A ER-SRC cells, v-SRC was cloned 
from the cDNA pool of the original MCF10A ER-SRC cell line.  Subsequently, pWZL 
Blast Twist ER plasmid (Addgene Plasmid #18799) was digested by BamHI to remove the 
Snai1 cDNA, and replaced with v-SRC cDNA, resulting in the expression of the fusion 
protein, v-SRC-ER, by the new recombinant plasmid.  This plasmid was subsequently used 
to produce retrovirus for infecting MCF10A cells.  Stable clones were selected by 
blasticidin.  Isolation of the EPTH and MES populations of CD44+CD24-/low MCF10A ER-
SRC transformed cells using flow cytometry has been previously described (130).  EPTH 
and MES cells were cultured as subclones for 2-3 passages and used for experiments.  
MDA-MB-231 and MDA-MB-435 cells were obtained from the American Type Culture 
Collection.  All experiments were performed at a cell density of 25-35%.       
Transfection and siRNA Knockdown  
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For overexpression, plasmids were transfected using Lipofectamine 2000 (Thermo Fisher 
Scientific).  Cells were processed for immunoblotting, qPCR or mammosphere formation 
approximately 24 hours following transfection.  For LATS 1/2 siRNA knockdown, MDA-
MB-231 cells were transfected using DharmaFect 4 (Dharmacon).  Cells were processed 
for immunoblotting 48 hours following transfection.  LATS 1/2 siRNA has been previously 
described (129).      
Mammosphere Assay  
Cells were plated in UltraLow attachment 6 well plates in DMEM/F12 medium 
supplemented with B27, EGF and fibroblast growth factor as previously described (130).  
For serial passaging, mammospheres were pelleted and dissociated with 0.05% Trypsin for 
15 minutes at 37 degrees Celsius to obtain single cells.  These cells were washed in 1X 
PBS, counted and re-plated in UltraLow attachment 6 well plates.    
Immunolotting 
Cells were washed in 1X PBS and scraped on ice in RIPA buffer with EDTA and EGTA 
(BP-115DG, Boston Bioproducts) supplemented with protease and phosphatase inhibitors 
(Pierce, #88669).  Laemmli 6X SDS sample buffer (BP-111R, Boston Bioproducts) was 
added to each sample and the protein lysate was boiled for 10 minutes and separated using 
SDS-PAGE.  Rac activity was assessed using a GST fusion protein containing the 
Rac/cdc42 binding domain of PAK (PBD) as previously described (124, 172).   
Luciferase Reporter Assay 
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TEAD transcriptional activity was assessed using a luciferase reporter construct 
(8XGTIIC-Addgene #34615) with the Dual-Luciferase Reporter Assay System (#E2940, 
Promega).  Approximately 24 hours following transfection, luciferase activity was 
measured as the average ratio of firefly to Renilla luciferase.      
Real time quantitative PCR 
RNA extraction was accomplished using an RNA isolation kit (BS88133, Bio Basic Inc) 
and cDNAs were produced using qScrict cDNA synthesis kit (#95047, Quantabio).  SYBR 
green (Applied Biosystems) was used as the qPCR master mix.  Experiments were 
performed in triplicate and normalized to GAPDH.  qPCR primer sequences were obtained 
from the Massachusetts General Hospital/Harvard Medical School PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/).         
Chromatin Immunoprecipitation (ChIP) 
ChiP was performed using ChIP-IT Express Chromatin Immunoprecipitation kit (Active 
Motif).  Antibodies used were TEAD4 (N-G2, Santa Cruz Biotechnology) and TAZ 
(70148S, Cell Signaling Technologies).  The following qPCR primer sequence was used 
to amplify the region of the TEAD4 peak in the β2-chimaerin promoter identified in 
ENCODE: Forward primer 5’-GCTTACAGCTGGCTTCACTT-3’ Reverse Primer 5’-
GGCCGAGAGAGAGAGAGTTT-3’.  
Immunoflourescence Confocal Microscopy 
TAZ localization was performed by fixing cells with paraformaldehyde (4%) and 
permeabilizing them with Triton X-100 (0.1%) as described (111, 129).  Cells were 
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blocked with 1% BSA and horse serum (2.5%) and incubated with TAZ antibody (1:100 
dilution; sc-48805, Santa Cruz Biotechnology) overnight at 4°C.  Subsequently, cells were 
washed with 1X PBS and incubated with fluorochrome-conjugated secondary antibodies.  
Images were captured at 20X magnification using a confocal microscope (Zeiss).    
ENCODE Data Analysis   
Encode TEAD4 binding signals were downloaded from www.encodeproject.org in bigwig 
format.  The coverages of duplicate samples were pooled and then plotted along the 
promoter region of the β2-chimaerin (CHN2) gene.      
cBioPortal Analysis  
cBioPortal (www.cbioportal.org) was utilized to compare the mRNA expression (RNA Seq 
V2 RSEM) of TAZ, VEGFA, NRP2 and β2-chimaerin using the TCGA invasive breast 
carcinoma provisional dataset (162, 163).  In addition, the mRNA expression (RNA Seq 
V2 RSEM) of TAZ and β2-chimaerin was compared in the TCGA glioblastoma provisional 
dataset and the TCGA colorectal adenocarcinoma Nature 2012 dataset.  The cancer cell 
line encyclopedia (Novartis/Broad, Nature 2012) was used to compare the expression of 
TAZ and β2-chimaerin across various cell lines using the mRNA expression z-scores 
microarray.  To determine whether the expression of two genes are inversely correlated, 
we performed the mutual exclusivity analysis with a z-score threshold of ± 1.5 as 
expressed, and calculated the log odds ratio between the two genes and p value using Fisher 
exact t-test.  In addition, we stratified breast cancer patients in the TCGA Cell 2015 
database based on their ER status, and compared β2-chimaerin expression in the ER+ and 
ER- subgroups using Welch t-test.         
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Microarray Data Analysis 
The microarray dataset from GEO (GSE48204) (166) was download using the 
Bioconductor package GEOquery (version 2.41.0).  Moderated t-test was used to identify 
differentially expressed genes between TGF-β induced EMT cells and NMuMG cells 
treated with vehicle.  Genes with an adjusted p-value of ≤ 0.05 using B-H method were 


























Figure 2.1: VEGF-NRP2 Signaling Contributes to TAZ Activation.  Expression of 
NRP2 (A) and VEGF (B) was diminished in MES cells and the impact on TAZ abundance 
was quantified by immunoblotting.  Representative blots are shown.  Densitometric values 
were processed using ImageJ and are provided as bar graphs (mean ± SEM) of n = 3 
biological replicates.  C.) TAZ localization (cytoplasm, nucleus/cytoplasm and nucleus) in 
control and VEGF-depleted MES cells was determined by immunofluorescence confocal 
microscopy.  Data are mean of n = 3 biological replicates.  D.) mRNA expression of the 
indicated TAZ target genes was quantified by qPCR in NRP2-depleted MES cells.  Data 
are mean ± SEM of n = 3 biological replicates.  E.) MES cells were treated with the 
indicated concentrations of a function-blocking NRP2 antibody for 6 hours and the impact 
on TAZ abundance was quantified by immunoblotting.  Representative blots are shown.  
Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 biological 
replicates of MES cells treated with 3 µg/mL of the NRP2 function-blocking antibody.  F.) 
NRP2 expression was diminished in MDA-MB-231 cells and the impact on TAZ 
abundance  was quantified by immunoblotting.  Representative blots are shown.  
Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 biological 
replicates.  G.) mRNA expression of the indicated TAZ target genes was quantified by 
qPCR in NRP2-depleted MDA-MB-231 cells.  Data are mean ± SEM of n = 3 biological 
replicates.  H.) NRP2-depleted MDA-MB-231 cells were transfected with an 8XGTIIC-
luciferase reporter construct and assayed for TEAD transcriptional activity.  Data are mean 





Figure 2.2: VEGF-NRP2 Signaling Activates Rac1.  A.) Expression of VEGF was 
diminished in MES cells and the impact on Rac1 activity was assessed using a GST fusion 
protein containing the Rac/cdc42 binding domain of PAK (PBD).  Representative blots are 
shown.  Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 biological 
replicates.  B.) MES cells were treated with 3 µg/mL of a function blocking NRP2 antibody 
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for 6 hours and assayed for Rac1 activity.  Representative blots are shown.  Densitometric 
values are provided as bar graphs (mean ± SEM) of n = 3 biological replicates.  C.) NRP2 
expression was diminished in MDA-MB-231 cells and the impact on Rac1 activity was 
assessed.  Representative blots are shown.  Densitometric values are provided as bar graphs 
(mean ± SEM) of n = 3 biological replicates.  D.) MDA-MB-231 cells were serum-starved 
for 24 hours, treated with 50 ng/mL of VEGF for 30 minutes and assayed for Rac1 activity.  
Representative blots are shown.  Densitometric values are provided as bar graphs (mean ± 
SEM) of n = 3 biological replicates.  E.) MES cells were treated with 2 µM of FAK14 for 
the indicated time points and assayed for Rac1 activity.  Representative blots are shown.  
Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 biological 
replicates of MES cells treated with FAK14 for 6 hours.  F.) NRP2 expression was 
diminished in MDA-MB-231 cells that were then transfected with constitutively active 
V12 Rac1-GST.  GST expression was quantified by immunoblotting.  mRNA expression 
of the indicated TAZ target genes was quantified by qPCR.  Data are mean ± SEM of n = 
3 biological replicates.  G.) MES cells were treated with 50 µM of the Rac inhibitors 
EHT1864 or NSC23766 and assayed for self-renewal by serial passage mammosphere 
formation (P1: passage 1; P2: passage 2).  Data are mean ± SEM of n = 3 biological 












Figure 2.3: Rac1 Facilitates VEGF-NRP2 Activation of TAZ through Inhibition of 
LATS.  A.) MES cells were treated with the indicated concentrations of the Rac inhibitor 
EHT1864 for 2 hours and the impact on pSer89 TAZ and TAZ abundance  was quantified 
by immunoblotting.  Representative blots are shown.  Densitometric values are provided 
as bar graphs (mean ± SEM) of n = 3 biological replicates.  B.) MES cells were treated 
with the Rac inhibitor EHT1864 (100 µM), lysed at the indicated time points and the impact 
on pThr1079 LATS1, LATS1 and TAZ abundance  was quantified by immunoblotting.  Data 
are representative of n = 2 biological replicates.  C.) MES cells were transfected with 
dominant negative N17 Rac1-HA and the impact on TAZ abundance  was quantified by 
immunoblotting.  Data are representative of n = 2 biological replicates.  D.) MES cells 
were treated with the indicated concentrations of a function-blocking NRP2 antibody for 6 
hours and the impact on pSer89 TAZ and TAZ abundance  was quantified by 
immunoblotting.  Representative blots are shown.  Densitometric values are provided as 
bar graphs (mean ± SEM) of n = 3 biological replicates of MES cells treated with 3 µg/mL 
of the NRP2 function-blocking antibody.  E.) NRP2 expression was diminished in MDA-
MB-231 cells and the impact on pSer89 TAZ and TAZ abundance  was quantified by 
immunoblotting.  Representative blots are shown.  Densitometric values are provided as 
bar graphs (mean ± SEM) of n = 3 biological replicates.  F.) NRP2 expression was 
diminished in MDA-MB-231 cells and the impact on pThr1079 LATS1 and LATS1 was 
quantified by immunoblotting.  Data are representative of n = 2 biological replicates.  G.)  
NRP2-depleted MDA-MB-231 cells were transfected with empty vector, wild-type TAZ 
or S89A TAZ and assayed for self-renewal by serial passage mammosphere formation.  
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Data are mean ± SEM of n = 3 biological replicates.  H.)  VEGF-depleted MES cells were 
transfected with empty vector, wild-type TAZ or S89A TAZ and assayed for self-renewal 
by serial passage mammosphere formation.  Error bars indicate standard deviation from 3 
technical replicates.  Data are representative of n = 2 biological replicates.  * p ≤ 0.05 by 







Figure 2.4: VEGF-NRP2 Signaling Represses the Rac GAP β2-chimaerin.  A.) 
Abundance of β2-chimaerin was quantified by immunoblotting in EPTH and MES cells.  
Representative blots are shown.  Densitometric values are provided as bar graphs (mean ± 
SEM) of n = 3 biological replicates.  B.) Expression of NRP2 was diminished in MES cells 
and β2-chimaerin mRNA expression was quantified by qPCR.  Data are mean ± SEM of n 
= 3 biological replicates.  C.) β2-chimaerin abundance was quantified by immunoblotting 
in NRP2-depleted MES cells.  Representative blots are shown.  Densitometric values are 
provided as bar graphs (mean ± SEM) of n = 3 biological replicates. D.)  MES cells were 
treated with the indicated concentrations of a function blocking NRP2 antibody for 6 hours 
and abundance of β2-chimaerin was quantified by immunoblotting.  Representative blots 
are shown.  Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 
biological replicates of MES cells treated with 3 µg/mL of the NRP2 function-blocking 













Figure 2.5: TAZ Activates Rac1 by Repressing β2-chimaerin.  A.) TAZ expression was 
diminished in MES cells and the impact on β2-chimaerin mRNA expression was quantified 
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by qPCR.  Data are mean ± SEM of n = 3 biological replicates. (B and C) β2-chimaerin 
abundance (B) and Rac1 activity (C) were assessed in TAZ knockdown MES cells.  
Representative blots are shown.  Densitometric values are provided as bar graphs (mean ± 
SEM) of n = 3 biological replicates.  D.) TAZ expression was diminished in MDA-MB-
435 cells and the impact on β2-chimaerin mRNA expression was quantified by qPCR. Data 
are mean ± SEM of n = 3 biological replicates.  E.) TAZ expression was diminished in 
MDA-MB-231 cells and the impact on β2-chimaerin mRNA expression was quantified by 
qPCR.  Data are mean ± SEM of n = 3 biological replicates.  F.) MDA-MB-231 cells were 
transfected with TAZ and the impact on β2-chimaerin mRNA expression was quantified 
by qPCR.  Data are mean ± SEM of n = 3 biological replicates.  G.) MES cells were treated 
with the indicated concentrations of the Rac inhibitor EHT1864 for 2 hours and β2-
chimaerin mRNA expression was quantified by qPCR.  Data are mean ± SEM of n = 3 













Figure 2.6: TEAD Mediates Repression of β2-chimaerin by TAZ.  A.) Using ENCODE, 
TEAD4 binding signals were analyzed from ChIP-seq datasets from h1-hESCs (human 
embryonic stem cells), HCT116 (colon cancer), Ishikawa (endometrial adenocarcinoma) 
and SK-N-SH (neuroblastoma) cells in the promoter region of the β2-chimaerin gene.  B.) 
Binding of TEAD4 and TAZ on the β2-chimaerin promoter was analyzed using ChIP in 
MES cells.  Error bars indicate standard deviation from 3 technical replicates.  Data are 
representative of n = 2 biological replicates.  C.) TEAD 1/3/4 expression was diminished 
in MES cells and the impact on β2-chimaerin mRNA expression was quantified by qPCR.  
Data are mean ± SEM of n = 3 biological replicates. (D and E) β2-chimaerin abundance 
(D) and Rac1 activity (E) were assessed in TEAD 1/3/4 knockdown MES cells.  
Representative blots are shown.  Densitometric values are provided as bar graphs (mean ± 
SEM) of n = 3 biological replicates.  F.) β2-chimaerin mRNA expression was quantified 
by qPCR in MDA-MB-231 cells expressing either a control vector or dominant-negative 
TEAD4.  Data are mean ± SEM of n = 3 biological replicates.  * p ≤ 0.05 by two-tailed t 





























Figure 2.7: β2-chimaerin Repression Contributes to Enhanced TAZ activity.  A.) 
MDA-MB-231 cells were transfected with Myc-tagged β2-chimaerin and Rac1 activity 
and TAZ abundance were assessed.  Representative blots are shown.  Densitometric values 
are provided as bar graphs (mean ± SEM) of n = 3 biological replicates.  B.) mRNA 
expression of the indicated TAZ target genes was quantified by qPCR in MDA-MB-231 
cells transfected with Myc-tagged β2-chimaerin.  Data are mean ± SEM of n = 3 biological 
replicates.  C.) Expression of β2-chimaerin was diminished in EPTH cells and the impact 
on Rac1 activity and TAZ abundance were assessed.  Representative blots are shown.  
Densitometric values are provided as bar graphs (mean ± SEM) of n = 3 biological 
replicates.  D.) mRNA expression of the indicated TAZ target genes was quantified by 
qPCR in β2-chimaerin-depleted EPTH cells.  Data are mean ± SEM of n = 3 biological 
replicates.  E.) β2-chimaerin-depleted EPTH cells were assayed for self-renewal by serial 
passage mammosphere formation (P1: passage 1; P2: passage 2).  Data are mean ± SEM 
of n = 3 biological replicates.  F.)  MDA-MB-231 cells were transfected with empty vector, 
wild-type TAZ or S89A TAZ with and without Myc-tagged β2-chimaerin and assayed for 
self-renewal by serial passage mammosphere formation.  Error bars indicate standard 
deviation from 3 technical replicates.  Data are representative of n = 2 biological replicates.  
G.) cBioPortal for cancer genomics was used to compare TAZ expression with β2-
chimaerin, NRP2 and VEGFA expression in the invasive breast carcinoma dataset from 
the Cancer Genome Atlas (TCGA).  The expression of TAZ vs. β2-chimaerin was also 
compared in the TCGA glioblastoma and colorectal adenocarcinoma databases as well as 
the cancer cell line encyclopedia (967 cell lines).  Log odds ratios and p values were 
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calculated using fisher exact t test with the mutual exclusivity tool on cBioPortal.  H.)  
cBioPortal for cancer genomics was used to analyze the expression of β2-chimaerin in ER+ 
vs. ER- breast cancer patients from the TCGA invasive breast carcinoma database. * p ≤ 






















Figure 2.8: Model depicting the major findings of this study.  VEGF-NRP2 signaling 
promotes FAK-mediated Rac1 activation, which inhibits LATS.  Consequently, TAZ is 
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located in the nucleus where it associates with TEAD and represses the Rac GAP β2-














Figure 2.9. VEGF-NRP2 Signaling Contributes to YAP Activation.   (A) TAZ 
localization (green) in control and VEGF-depleted MES cells was determined by 
immunofluorescence confocal microscopy.  The nucleus is stained with DAPI (blue).  
Scale bar, 20 μm.  Data are representative of n = 3 biological replicates.  (B) Expression of 
NRP2 was diminished in MES cells and the impact on pSer127 YAP and YAP abundance 
was assessed by immunoblotting.  Data are representative of n = 2 biological replicates. 
(C) Expression of VEGF was diminished in MES cells and the impact on YAP abundance 

















Figure 2.10. VEGF-NRP2 Activation of Rac1 is independent of VEGFR.   MDA-MB-
231 cells were serum-starved for 24 hours, treated with VEGF (50 ng/mL) with or without 
Pazopanib or Sunitinib (as indicated; each 2 µM) for 30 min and assayed for Rac1 activity.  
Representative blots are shown.  Densitometry are mean ± SEM of n = 3 biological 














Figure 2.11. VEGF-Neuropilin-2-Rac1 Regulation of Merlin Phosphorylation 
(pSer518) is LATS Dependent.  (A)  NRP2 expression was diminished in MDA-MB-231 
cells which were then transfected with control siRNA or LATS 1/2 siRNA (20 nM).  
Approximately 48 hours after transfection, the impact on TAZ abundance was assessed by 
immunoblotting.  Data are representative of n = 2 biological replicates.  (B) MES cells 
were treated with the indicated concentrations of the Rac inhibitor EHT1864 for 2 hours 
and the impact on pSer518 Merlin and Merlin was assessed by immunoblotting.  Data are 
58 
 
representative of n = 2 biological replicates.  (C) NRP2 expression was diminished in MES 
cells and the impact on pSer518 Merlin and Merlin was quantified by immunoblotting.  
Representative blots are shown.  Densitometric values are provided as bar graphs (mean ± 



























Figure 2.12. Expression of Wild-Type and S89A TAZ Constructs.    MDA-MB-231 























Figure 2.13. β2-chimaerin is Repressed by the EMT.   The indicated genes from a 
microarray (accession number GSE48204) using TGF-β to induce an EMT in NMuMG 
mammary epithelial cells were analyzed.  Log fold change (fc) in expression and adjusted 


















 EPTH MES 
GEFs   
PRex1 NE NE 
PRex2 NE NE 
Tiam1 1 (0.13) 0.52 (0.04) 
Tiam2 NE NE 
SOS1 1 (0.01) 0.62 (0.04) 
ARHGEF7 1 (0.08) 1.1 (0.01) 
Dock1 1 (0.08) 0.56 (0.13) 
VAV1 NE NE 
VAV2 1 (0.07) 0.63 (0.02) 
VAV3 1 (0.1) 0.69 (0.17) 
Trio 1 (0.05) 0.76 (0.02) 
GAPs   
β2-chimaerin 1 (0.08) 0.16 (0.07) 
ARHGAP10 1 (0.05) 0.7 (0.05) 
 
Table 2.1: mRNA screen of Rac GEFs and GAPs in EPTH and MES cells.  The 
expression of the indicated Rac GEFs and GAPs was compared in EPTH and MES cells 
using qPCR.  Table 1 shows fold change in mRNA expression upon normalization with 
EPTH cells, which was set as 1.  NE indicates not expressed.  Numbers in parentheses 
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The role of vascular endothelial growth factor (VEGF) in cancer is not limited to 
angiogenesis and vascular biology (34, 35, 41, 115).  Tumor cells express VEGF receptors 
and VEGF signaling in these cells has been implicated in the aggressive nature and 
chemoresistance of many cancers, independently of its function in angiogenesis (42).  In 
addition to tyrosine kinase VEGF receptors (VEGFR1 and VEGFR2), tumor cells express 
neuropilins (NRPs), another family of VEGF receptors.  Although NRPs have the ability 
to interact with and regulate VEGFR1 and VEGFR2 (62, 117), they can also mediate 
VEGF signaling in tumor cells independently of these tyrosine kinase receptors (45, 60, 
63, 64, 174).  The fact that VEGF-NRP signaling is characteristic of more aggressive 
tumors that often respond poorly to therapy has profound clinical implications and it 
heightens the importance of understanding how VEGF-NRP signaling promotes resistance.  
This problem is exemplified in aggressive breast cancers, such as the triple-negative 
subtype (TNBC), that manifest VEGF-NRP2 signaling (68) and are resistant to standard 
therapy (8).         
One potentially promising area that has not been explored rigorously with respect 
to VEGF-NRP signaling in breast and other cancers is its contribution to DNA repair 
pathways.  The integrity of such pathways is a major reason for resistance to therapy.  
Specifically, the ability to execute efficient homologous recombination (HR) DNA repair 
is considered to be critical for the ability of tumors to resist platinum-based 
chemotherapies, poly (ADP-ribose) polymerase (PARP) inhibitors and radiation therapy 
(175).  Conversely, HR deficiency, which is most often attributed to germline BRCA 1/2 
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mutations or loss of BRCA 1 expression through promoter hypermethylation in breast 
cancer, provides an ‘Achilles heel’ that renders sensitivity to these agents.  For example, 
clinical studies have demonstrated favorable outcomes of TNBC patients with HR 
deficiency treated with neoadjuvant platinum chemotherapy (28, 30-33).  However, only 
11-15% of TNBC patients harbor germline BRCA mutations (25, 27), a fact that indicates 
that many TNBCs are HR proficient and, consequently, resistant to therapies that induce 
DNA damage.  In this study, we investigated the potential contribution of VEGF-NRP2 
signaling to HR in breast cancer cells, and we pursued the mechanism involved.  The results 
obtained validate our hypothesis and they reveal that VEGF-NRP2 signaling regulates 
Rad51, a central HR enzyme that catalyzes homology strand exchange and facilitates the 
repair of damaged DNA (176).  Importantly, we also made the novel observation that the 
ability of VEGF-NRP2 signaling to regulate Rad51 is mediated by YAP/TAZ and that 
Rad51 is a novel YAP/TAZ target gene.     
 
Results 
VEGF-NRP2 promotes protection from DNA damaging agents.  Initially, we 
assessed the potential contribution of NRP2 and VEGF in the response of TNBC cells to 
DNA damage.  We focused our attention on cisplatin because platinum chemotherapy is 
particularly effective for tumors with HR deficiency (28, 30-33).  For this purpose, we 
depleted NRP2 and VEGF with short hairpin RNAs (shRNAs) in MDA-MB-231 cells, a 
BRCA 1 wild type TNBC cell line (177) that exhibits VEGF-NRP2 signaling (63, 130), 
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and assessed DNA damage by measuring γH2AX levels.  We observed that NRP2 and 
VEGF depletion resulted in increased DNA damage in comparison to cisplatin-treated 
control cells (Fig. 3.1A).  Similar results were obtained with NRP2 depletion in response 
to cisplatin in Hs578t cells, which are another BRCA 1 wild type TNBC cell line (177) that 
expresses VEGF and NRP2 (Fig. 3.1B).  Negligible γH2AX was detected under baseline 
conditions in control and NRP2 and VEGF depleted MDA-MB-231 cells (Fig. 3.8A).         
 VEGF-NRP signaling can function in TNBC and other cancer cells independently 
of the VEGFRs (45, 60, 63, 64, 174).  This observation is significant because bevacizumab, 
the most common anti-VEGF therapy, blocks VEGF binding to VEGFRs, but it does not 
disrupt the VEGF-NRP association or signaling (2).  To assess the relative contribution of 
NRP2 and VEGFRs to the protection of TNBC cells from cisplatin-induced DNA damage, 
we treated Hs578t cells with cisplatin in the presence of a NRP2-function blocking 
antibody (65) or bevacizumab and observed that NRP2 inhibition resulted in increased 
γH2AX abundance relative to cisplatin-treated control cells, but that bevacizumab did not 
(Fig. 3.1C).  We substantiated these results by treating BRCA proficient mouse mammary 
tumor organoids, which were established to exhibit resistance to HR-inducing agents (178), 
with either cisplatin, the NRP2 function blocking antibody, bevacizumab, or combinations 
of these reagents, and observed that NRP2 inhibition sensitizes these tumor organoids to 
cisplatin but that bevacizumab does not (Fig. 3.1D).  These findings indicate that VEGF-
NRP2 signaling mediates protection from cisplatin-induced DNA damage independently 
of the VEGFRs.      
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 Following the results obtained with cisplatin, we next sought to determine if VEGF-
NRP2 mediates resistance to a broader variety of agents used in TNBC.  We focused our 
attention on PARP inhibition and ionizing radiation (IR).  Indeed, we observed that NRP2 
depletion sensitizes Hs578t cells to olaparib (Fig. 3.8B) and IR (Fig. 8C).  Similar to our 
results with cisplatin, treatment of Hs578t cells with IR and the NRP2 function blocking 
antibody resulted in increased γH2AX abundance compared to radiation-treated control 
cells (Fig. 3.8D).    
YAP/TAZ are necessary for VEGF-NRP2 protection from cisplatin-induced DNA 
damage.  The hippo pathway transducers YAP and TAZ are critical downstream effectors 
of VEGF signaling in several distinct cell types (179).  Moreover, VEGF-NRP2 activation 
of YAP/TAZ in TNBC cells occurs through a VEGFR-independent mechanism (63).  For 
these reasons, we hypothesized that VEGF-NRP2 promotes genomic integrity and cisplatin 
resistance through downstream YAP/TAZ activation.  To test this hypothesis, we assessed 
DNA damage in response to cisplatin in NRP2-depleted Hs578t cells expressing the S89A 
TAZ mutant, which is resistant to inhibitory phosphorylation at that site (127), or empty 
vector and found that S89A TAZ rescued the increase in γH2AX observed upon NRP2 
depletion (Fig. 3.2A).  Importantly, S89A TAZ also rescued cell viability in NRP2-
depleted Hs578t cells treated with cisplatin (Fig. 3.2B).  Similar results were obtained in 
Hs578t cells expressing S127A YAP, which is resistant to inhibitory phosphorylation at a 
homologous phosphorylation site (Fig. 3.2C and D) (127).  Together, these data provide 
evidence that VEGF-NRP2 signaling protects the genome from DNA damage caused by 
cisplatin by a mechanism that involves downstream YAP/TAZ activation.          
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YAP/TAZ facilitate homologous recombination and contribute to Rad51 
expression.  Given that YAP/TAZ rescued the defects in DNA repair and cell viability in 
NRP2-depleted cells in response to cisplatin (Fig. 3.2), we assessed the potential 
contribution of YAP and TAZ to HR.  For this purpose, we utilized the well-established 
HR reporter assay (DR-GFP) (180).  This assay is based on the expression of functional 
GFP as a result of HR in response to a double-strand break induced by the I-SceI 
endonuclease, which can be quantified by flow cytometry.  For this assay, we used MCF7 
cells, a BRCA 1 wild type ER+ breast cancer cell line (177), engineered to stably express 
DR-GFP because they exhibit low YAP/TAZ activity.  Consequently, expression of 
YAP/TAZ in these cells provides a robust system to study their role in HR.  To ensure that 
the expressed YAP/TAZ were active, we used the S89A TAZ and S127A YAP mutants, 
which are resistant to inhibitory phosphorylation at those sites (127).  Expression of either 
of these mutants in DR-GFP MCF-7 cells resulted in a significant increase in the number 
of GFP-positive cells following a double-strand break by I-SceI compared to control cells, 
providing evidence that YAP/TAZ contribute to HR (Fig. 3.3A and Fig. 3.9A, B).       
To identify the mechanism by which YAP/TAZ promote HR, we analyzed 
published microarray data (GSE59230) (181) derived from YAP/TAZ depletion in MDA-
MB-231 cells for significant alterations in the expression of genes that could contribute to 
HR.  Most notably, the mRNA expression of Rad51, a central HR enzyme that catalyzes 
homology strand exchange and facilitates the repair of damaged DNA (176), was reduced 
in this microarray dataset upon YAP/TAZ depletion to a similar degree as the established 
YAP/TAZ target genes CTGF and Cyr61 (Fig. 3.3B).  Rad51 mediates resistance of TNBC 
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cells to therapy (182), and its expression is up-regulated in breast and other cancer cells 
(182, 183), which may result from increased activity at its promoter (184, 185).  However, 
mechanisms that control Rad51 transcription and function in specific tumors are poorly 
understood.  Given this information, we developed the hypothesis that VEGF-NRP2 
facilitates YAP/TAZ-mediated Rad51 expression and HR in TNBC.      
Initially, we assessed whether a correlation exists between enhanced YAP/TAZ 
activity and Rad51 expression in patient samples.  A YAP/TAZ gene signature, as well as 
elevated TAZ mRNA expression, is associated with hormone receptor negative, high-grade 
breast tumors (110, 111).  Therefore, we analyzed the expression of Rad51 and compared 
it to markers of enhanced YAP/TAZ activity in patient tumors in the Metabric breast cancer 
database obtained from cBioPortal (162, 163).  Specifically, we observed that Rad51 
expression is higher in ER- tumors compared to ER+ tumors (Fig. 3.3C) and that Rad51 
expression correlates positively with breast tumor grade (Fig. 3.3D), as well as with TAZ 
and the YAP/TAZ target genes CTGF and Cyr61 (Fig. 3.3E).   We validated a causal role 
for YAP/TAZ in regulating Rad51 in MDA-MB-231 cells (Fig. 3.4A).  Similarly, we 
observed that siRNA knockdown of YAP/TAZ in Hs578t cells reduced Rad51 abundance 
(Fig. 3.4B).  Consistent with our results using YAP/TAZ siRNA, MDA-MB-231 cells with 
stable depletion of TAZ and treated with verteporfin to inhibit YAP exhibited a decrease 
in Rad51 mRNA expression (Fig. 3.4C).  Similar results were obtained when assessing 
Rad51 protein abundance in response to shTAZ alone, verteporfin alone or the combination 
in MDA-MB-231 cells (Fig. 3.4D).  A reduction in nuclear and total Rad51 abundance was 
also observed by immunofluorescence microscopy in YAP/TAZ-depleted MDA-MB-231 
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cells treated with cisplatin to induce HR (Fig. 3.4E).  Conversely, expression of S89A TAZ 
in MCF7 DR-GFP cells increased Rad51 abundance (Fig. 3.4F).  Together, these data 
indicate that a YAP/TAZ-Rad51 axis contributes to efficient HR in TNBC cells.          
Rad51 is a YAP/TAZ-TEAD target gene.  YAP/TAZ-mediated transcriptional 
regulation occurs through the TEAD 1-4 family of transcription factors (127, 146).  
TEAD4, in particular, has been shown to play a dominant role in TNBC (158, 159).  In 
light of this information, we analyzed the encyclopedia of DNA elements (ENCODE) 
database for TEAD4 chromatin immunoprecipitation sequencing (ChIP-seq) experiments 
to determine if YAP/TAZ-dependent control of Rad51 expression occurs through a direct 
mechanism mediated by TEAD.  We found four cell types in ENCODE (h1-human 
embryonic stem cells (hESCs), HCT116 colon cancer cells, Ishikawa endometrial 
adenocarcinoma cells and SK-N-SH neuroblastoma cells), which have been previously 
shown to have enhanced YAP/TAZ activity (161, 186), where TEAD4 bound directly to 
the promoter region of Rad51 (Fig. 3.5A).  Subsequently, we performed ChIP in MDA-
MB-231 and Hs578t cells to validate direct binding of TEAD4 to the Rad51 promoter in 
TNBC cells (Fig. 3.5B).  To obtain additional evidence to implicate TEAD4 in Rad51 
transcription, we used a Rad51 promoter luciferase assay (185).  We expressed this reporter 
construct in MDA-MB-231 cells stably expressing dominant negative TEAD4 and 
observed a reduction in luciferase activity at the Rad51 promoter (Fig. 3.5C).  Dominant 
negative TEAD4 also caused a decrease in Rad51 abundance (Fig. 3.5D).  These results 
provide evidence that a YAP/TAZ-TEAD transcriptional program governs Rad51 
expression and activity in TNBC.      
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Rad51 mediates VEGF-NRP2-YAP/TAZ-dependent DNA repair.  A key issue that 
emerges from these findings is the role of YAP/TAZ-mediated Rad51 expression in DNA 
repair in the cellular response to cisplatin.  As shown in Fig. 6A and B, YAP/TAZ 
depletion in Hs578t cells treated with cisplatin resulted in increased DNA damage as 
measured by γH2AX in comparison to cisplatin-treated control cells.  Importantly, re-
expression of Rad51 rescued the increase in γH2AX observed upon YAP/TAZ depletion 
(Fig. 3.6A, B and 3.10A).  These results substantiate the data shown in Fig. 3.3A and 
3.9A, B that YAP/TAZ contribute to HR and they provide evidence that YAP/TAZ-
mediated HR occurs through downstream Rad51 expression.  Similar to VEGF and NRP2 
downregulation, negligible γH2AX was observed under baseline conditions in YAP/TAZ 
depleted Hs578t cells (Fig. 3.10B).  We also assessed the effects of cisplatin and TAZ 
depletion on cell viability in MDA-MB-231 cells and observed that TAZ downregulation 
promotes cisplatin sensitization, which is rescued by Rad51 re-expression (Fig. 6C and 
3.10C).  Along these lines, we tested the effects of either cisplatin, verteporfin or the 
combination on BRCA proficient mouse mammary tumor organoids and observed that YAP 
inhibition with verteporfin sensitizes these tumor organoids to cisplatin (Fig. 3.6D), similar 
to the results obtained with NRP2 inhibition (Fig. 3.1D).          
Given that BRCA1 is required for Rad51-mediated HR (187), we hypothesized that 
YAP/TAZ should not affect DNA damage in BRCA1 mutant cells.  To test this hypothesis, 
we assessed DNA damage in response to cisplatin in SUM-1315 cells, which are a BRCA1 
mutant TNBC cell line (177).   Notably, although we detected a reduction in Rad51 
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abundance, we did not observe an increase in γH2AX in response to cisplatin in cells 
depleted of TAZ and treated with verteporfin to inhibit YAP (Fig. 3.11A and B).    
We postulated that the mechanism by which VEGF-NRP2 protects from DNA 
damage is through YAP/TAZ-mediated Rad51 expression.  This postulate is based on the 
finding that VEGF-NRP2 signaling is an important upstream regulator of YAP/TAZ (63) 
and our observations that YAP and TAZ rescued the defects in DNA repair in NRP2-
depleted cells (Fig. 3.2) and that Rad51 rescued the defects in DNA repair in YAP/TAZ-
depleted cells (Fig. 3.6A-C).  Indeed, we observed that both NRP2 and VEGF depletion in 
MDA-MB-231 cells reduced Rad51 abundance (Fig. 3.7A and B).  Stimulation of VEGF-
depleted MDA-MB-231 cells with exogenous VEGF rescued the increase in γH2AX and 
reduction in Rad51 abundance in response to cisplatin (Fig. 3.7C).  We also observed that 
treating Hs578t cells with the function-blocking NRP2 antibody reduces HR as measured 
by DR-GFP analysis (Fig. 3.7D and 3.12A).  Importantly, we observed that inhibiting 
NRP2 in cells ectopically expressing Rad51 does not influence HR (Fig. 7D and 3.12A).  
This result provides evidence that downstream Rad51 expression is critical for VEGF-
NRP2-mediated HR.  Similar to our results inhibiting YAP/TAZ (Fig. 3.6C and D), Rad51 
rescued cell viability in response to cisplatin in NRP2-depleted Hs578t cells (Fig. 7E and 
3.12B).  Lastly, in support of our in vitro data, we found that Rad51 expression correlates 
positively with VEGF and NRP2 in breast cancer patients in the Metabric dataset obtained 





The results of this study establish a significant and novel role for VEGF-NRP 
signaling in HR by promoting the expression and function of Rad51.  Importantly, we also 
demonstrate that this novel mechanism is mediated by YAP/TAZ and that Rad51 is a 
YAP/TAZ target gene.  These findings integrate salient characteristics of aggressive breast 
tumors: dependence on VEGF-NRP2 signaling (63, 68), hyper-activation of YAP/TAZ 
(110, 111) and high Rad51 expression (182, 188) into a unified mechanism that accounts 
for their therapy resistance.  They also provide one mechanism for how Rad51 transcription 
is regulated in cancer, an area that is poorly understood.       
Although many studies have revealed the importance of VEGF-NRP signaling in 
tumor cells, independently of its role in angiogenesis (42), its contribution to DNA repair 
mechanisms is novel and significant.  Of note, VEGF-NRP signaling has been implicated 
in drug resistance in multiple tumors but satisfying mechanisms have been elusive (64, 
189-191).  Given that efficient HR is a key determinant of such resistance, our results 
implicating this signaling in HR-directed repair provides one such mechanism as 
exemplified by the data we obtained with cisplatin, olaparib and IR in breast cancer cells 
and organoids.  Our results are timely because, for example, platinum chemotherapy has 
garnered interest in recent years as a therapeutic option for TNBC patients, especially those 
with loss of BRCA function and/or features of genomic instability (28, 30-33).  However, 
the majority of TNBC patients do not have germline BRCA mutations and, accordingly, 
platinum analogues do not provide these patients with significant clinical benefits over 
mechanistically distinct drugs (33).  We provide evidence for the causality of NRP 
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signaling in this resistance by demonstrating that HR-inducing agents are more efficacious 
in killing breast tumor cells and organoids when simultaneously inhibiting NRP2 function.         
The second major advance provided by our data is that the Hippo pathway 
transcriptional effectors YAP and TAZ contribute to HR by regulating Rad51 transcription.  
Although considerable evidence indicates that these transcriptional co-activators contribute 
to the aggressive behavior and therapy resistance of TNBC and other cancers (110, 113), 
much remains to be learned about their transcriptional targets and how they function.  From 
this perspective, our implication of their involvement in HR by regulating Rad51 is 
significant. Our previous work established that VEGF-NRP2 signaling activates YAP/TAZ 
(63), but the contribution of these critical Hippo effectors to DNA repair mechanisms was 
not known.  Our findings mesh with the emerging view that YAP/TAZ mediate the 
transcriptional addiction of cancer cells, a process implicated in drug resistance (113).  The 
implications of our data for therapy are potentially substantial because targeted inhibition 
of YAP/TAZ increases the sensitivity of breast cancer cells and organoids to cisplatin, 
which is similar to blocking NRP2.  Moreover, the selectivity that either NRP2 or 
YAP/TAZ inhibition is likely to display towards transcriptional-addicted tumors is a viable 
experimental approach and it has the potential to limit toxicities that may be associated 






Materials and Methods 
Reagents, antibodies and cell culture.  Verteporfin and cisplatin were purchased from 
Tocris, olaparib was purchased from Selleckchem and human VEGFA was purchased from 
R & D Systems.  The NRP2 function blocking antibody was provided by Genentech (65).  
Bevacizumab was provided by the UMASS Medical School oncology pharmacy.  Cisplatin 
was used at a concentration of 10 µM for 24 hours, verteporfin was used at a concentration 
of 2 µM for 24 hours, olaparib was used at a concentration of 20 µM for 24 hours and the 
NRP2 function blocking antibody and bevacizumab were used at a concentration of 10 
µg/mL for 24 hours.  Immunoblotting antibodies were acquired as follows: Actin (MA5-
15739, Thermo Fisher Scientific), TAZ (560235, BD Biosciences), YAP/TAZ (8418S, 
Cell Signaling Technologies), Rad51 (8875S, Cell Signaling Technologies), NRP2 
(AF2215, R & D Systems), γH2AX (05-636, Millipore), HA-tag (3724S, Cell Signaling 
Technologies), FLAG-tag (F3165, Sigma-Aldrich) and Myc-tag (2278S, Cell Signaling 
Technologies).  MDA-MB-231 and Hs578t were obtained from the American Type Culture 
Collection and SUM-1315 cells were provided by Dr. Stephen Ethier.      
Constructs, transfection and siRNA knockdown.  shNRP2, shVEGF, shTAZ, S89A TAZ 
pcDNA 3.1 and Myc-tagged dominant negative TEAD4 were used as previously described 
(63).  Retroviral S127A YAP (plasmid #33092) and lentiviral S89A TAZ (plasmid #52084) 
were purchased from Addgene.  Rad51 was provided by Dr. Maria Jasin (Memorial Sloan 
Kettering Cancer Cancer) (180).  Lipofectamine 3000 (Thermo Fisher Scientific) was used 
for plasmid expression and DharmaFect 4 (Dharmacon) was used for siRNA knockdown.  
YAP/TAZ siRNA has been previously described (100).        
75 
 
Cell viability assay and organoid culture.  To assess viability, cells were seeded and 
subsequently treated with cisplatin, olaparib, IR, the NRP2 function blocking antibody, 
bevacizumab, verteporfin, or combinations the following day as described in the figure 
legends.  After 24 hours, cells were washed with 1X phosphate-buffered saline (PBS) and 
complete medium was added.  Cells were counted 3 days following treatment using trypan 
blue exclusion.  Cell number was normalized to 1 based on the control sample.  BRCA 
proficient mammary tumor organoids were provided by Dr. Jos Jonkers (Netherlands 
Cancer Institute) and cell viability was assessed as previously described (178).         
Immunoblotting.  Cells were scraped on ice in RIPA buffer with EDTA and EGTA (BP-
115DG, Boston Bioproducts) supplemented with protease inhibitor cocktail (Roche, 
04693132001).  Subsequently, laemmli buffer (BP-111R, Boston Bioproducts) was added 
to each sample and the lysate was boiled and separated using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis.      
Luciferase reporter assay.  The Rad51 promoter luciferase construct was provided by Dr. 
Vera Gorbunova (University of Rochester) and Dual-Luciferase Reporter Assay System 
(#E2940, Promega) was used to asses Rad51 luciferase activity, which was measured as 
the average ratio of firefly to Renilla luciferase.       
Real-time qPCR.  An RNA isolation kit (BS88133, Bio Basic Inc) was used to extract RNA 
and cDNAs were synthesized using qScript cDNA kit (#95047, Quantabio).  The qPCR 
master mix used was SYBR green (Applied Biosystems).  Experiments were performed 
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with three technical replicates and normalized to GAPDH.  Rad51 qPCR primer sequence 
has been previously described (185).      
Chromatin immunoprecipitation.  ChIP-IT Express Chromatin Immunoprecipitation kit 
(Active Motif) was used for TEAD4 antibody (N-G2, Santa Cruz Biotechnology) ChiP 
experiments.  The following qPCR primer sequence was used to amplify the region of the 
TEAD4 signal in the Rad51 promoter identified in ENCODE: Forward primer 5’-
TTGCTCCAGGAATGCGAGTA-3’ Reverse primer 5’-AGCGCTCTTGTGGTTTGTTT-
3’.    
DR-GFP assay.  Puromycin resistant DR-GFP MCF7 cells were provided by Dr. Sharon 
Cantor (University of Massachusetts Medical School).  Stable expression of S89A TAZ 
(Addgene plasmid #52084) was accomplished by selecting cells in blasticidin and stable 
expression of S127A YAP (Addgene plasmid #33092) was accomplished by selecting cells 
in hygromycin.  DR-GFP reporter plasmid was purchased from Addgene and was 
electroporated into Hs578t cells (Addgene plasmid #26475).  Subsequently, cells were 
transfected with I-SceI (Addgene plasmid #26477) and processed for flow cytometry 72 
hours later using two-color fluorescence analysis (180) with DsRed.  FL1 indicates green 
fluorescence and FL2 indicates red fluorescence.  
Immunofluorescence microscopy.  Rad51 and γH2AX immunofluorescence microscopy 
was performed by fixing cells with paraformaldehyde (4%) and permeabilizing them with 
triton X-100 (0.1%).  Cells were blocked with 0.5% BSA and incubated with Rad51 
antibody (ab63801, Abcam) or γH2AX antibody (05-636, Millipore) overnight at 4°C.  The 
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following morning, cells were washed with 1X PBS and incubated with fluorochrome-
conjugated secondary antibodies at room temperature for 45 minutes.  A confocal 
microscope (Zeiss) was used to capture images at 20X magnification.  FociCounter 
http://focicounter.sourceforge.net/ was used to quantify γH2AX positive cells.       
ENCODE data analysis.  TEAD4 binding signals were downloaded 
from www.encodeproject.org in bigwig format.  The signals of duplicate samples were 
pooled and then plotted along the promoter region of the Rad51 gene using trackViewer 
package (193).           
Metabric analysis.  cBioPortal (www.cbioportal.org) was used to compare the mRNA 
expression of Rad51, TAZ, CTGF, Cyr61, VEGFA and NRP2 using the Metabric breast 
cancer dataset (162, 163).  To determine if the expression of two genes exhibit an inverse 
correlation, we performed the mutual exclusivity analysis with a z-score threshold of ± 2 
as expressed, and calculated the log odds ratio between two genes and p value using Fisher 
exact t-test.  We also stratified breast cancer patients in the Metabric dataset based on their 
ER status and tumor grade, and Welch t-test was used to compare Rad51 expression in ER+ 
and ER- and tumor grade 1-3 patient groups.              
Microarray analysis.  The Bioconductor package GEOquery (version 2.41.0) (194) was 
used to download the microarray dataset from GEO (GSE59230) (181).  Differentially 
expressed genes between MDA-MB-231 cells transfected with siRNA control and two 
different siRNAs targeting YAP/TAZ were identified using moderated t-test with limma 
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package (195).  Genes with an adjusted p-value of ≤ 0.05 using Benjamini-Hochberg 























Fig. 3.1.  VEGF-NRP2 promotes protection from cisplatin-induced DNA damage.  (A) 
Expression of NRP2 and VEGF was diminished with shRNAs in MDA-MB-231 cells.  
Subsequently, cells were treated with cisplatin and processed for γH2AX 
immunofluorescence microscopy.  Scale bar represents 50 µm.  (B) Expression of NRP2 
was diminished in Hs578t cells.  Subsequently, cells were treated with cisplatin and the 
impact on γH2AX abundance was quantified by immunoblotting.  Densitometry was 
assessed using ImageJ (right bar graph).  (C) Hs578t cells were treated with a control IgG, 
a NRP2 function antibody or bevacizumab in the presence of cisplatin and the impact on 
γH2AX abundance was quantified by immunoblotting.  Densitometry was assessed using 
ImageJ (right bar graph).  (D) Cell viability in BRCA proficient mouse mammary tumor 
organoids treated with a control IgG, a NRP2 function blocking antibody or bevacizumab 
with and without cisplatin was assessed.  Dot plots (mean ± standard deviation) represent 














Fig. 3.2.   YAP/TAZ are necessary for VEGF-NRP2 protection from cisplatin-induced 
DNA damage.  NRP2-depleted Hs578t cells expressing S89A TAZ or a control vector 
were treated with cisplatin and the impact on γH2AX abundance (A) and cell viability (B) 
was assessed.  Densitometry was assessed using ImageJ (right bar graph of B).  NRP2-
depleted Hs578t cells expressing S127A YAP or a control vector were treated with 
cisplatin and the impact on γH2AX abundance (C) and cell viability (D) was assessed.  Dot 
plots (mean ± standard deviation) represent three independent experiments.  * p ≤ 0.05, ** 















Fig. 3.3.  YAP/TAZ promote homologous recombination and correlate with Rad51 in 
patient tumors.  (A) DR-GFP MCF7 cells engineered to express S89A TAZ, S127A YAP 
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or empty vector were transfected with I-SceI and processed for flow cytometry to quantify 
GFP positive cells, which were normalized to 1 and are depicted as HR efficiency.  Dot 
plot (mean ± standard deviation) represents three independent experiments.  * p ≤ 0.05 by 
two-tailed t test.  (B) The indicated genes from a microarray (accession number GSE59230 
(181)) using siRNA to deplete YAP/TAZ in MDA-MB-231 cells were analyzed.  Log fold 
change in expression from four biological replicates is shown relative to siRNA control, 
and adjusted p value of ≤ 0.0005 is indicated by ***.  cBioPortal for cancer genomics was 
used to analyze the expression of Rad51 based on expression of the ER (C) and tumor 
grade (D) in breast cancer patients from the Metabric database.  *** p < 0.0005 by Welch 
t test.  (E)  The expression of Rad51 was compared with TAZ and the YAP/TAZ target 
genes CTGF and Cyr61 in the Metabric database.  Log odds ratios were generated and p 












Fig. 3.4.  YAP/TAZ contribute to Rad51 expression.  (A) Expression of YAP/TAZ was 
diminished with siRNAs in MDA-MB-231 cells and the impact on Rad51 mRNA 
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expression was quantified by qPCR.  (B) Rad51 abundance was quantified by 
immunoblotting in YAP/TAZ-depleted Hs578t cells.  Densitometry was assessed using 
ImageJ (right bar graph).  (C) Knockdown of TAZ was quantified by immunoblotting in 
MDA-MB-231 cells (left).  These cells were subsequently treated with verteporfin to also 
inhibit YAP and Rad51 mRNA expression was quantified by qPCR (right).  (D) Rad51 
abundance was quantified by immunoblotting in TAZ-depleted MDA-MB-231 cells, 
verteporfin-treated MDA-MB-231 cells and the combination.  (E) YAP/TAZ-depleted 
MDA-MB-231 cells were treated with cisplatin and the impact on Rad51 was assessed by 
immunofluorescence microscopy.  Scale bar represents 50 µm.  (F) DR-GFP MCF7 cells 
were transfected with either S89A TAZ or empty vector and Rad51 abundance was 
quantified by immunoblotting.  Densitometry was assessed using ImageJ (right bar graph).  
Dot plots (mean ± standard deviation) represent three independent experiments.  * p ≤ 0.05, 











Fig. 3.5.  Rad51 is a direct YAP/TAZ-TEAD target gene.  (A) TEAD4 binding signals 
from ENCODE were analyzed in ChIP-seq datasets from h1-hESCs (human embryonic 
stem cells), HCT116 (colon cancer), Ishikawa (endometrial adenocarcinoma) and SK-N-
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SH (neuroblastoma) cells in the promoter region of the Rad51 gene.  (B) Binding of TEAD4 
on the Rad51 promoter was analyzed using ChIP in MDA-MB-231 (left) and Hs578t (right) 
cells.  (C) MDA-MB-231 cells expressing dominant-negative TEAD4 were transfected 
with pRad51-Luc that utilizes the Rad51 promoter to control expression of firefly 
luciferase and assayed for Rad51 transcriptional activity.  (D) Rad51 abundance was 
quantified by immunoblotting in MDA-MB-231 cells expressing dominant-negative 
TEAD4.  Densitometry was assessed using ImageJ (right bar graph).  Dot plots (mean ± 
standard deviation) represent three independent experiments.  * p ≤ 0.05, ** p ≤ 0.005, *** 














Fig. 3.6.  Rad51 mediates YAP/TAZ-dependent DNA repair.  Expression of YAP/TAZ 
was diminished in Hs578t cells (siRNA YT).  Cells were then transfected with HA-tagged 
Rad51 or empty vector.  Subsequently, cells were treated with cisplatin and processed for 
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(A) immunofluorescence microscopy or (B) immunoblotting to quantify γH2AX.  Scale 
bar represents 50 µm.  (C) TAZ-depleted MDA-MB-231 cells expressing Rad51 or a 
control vector were treated with cisplatin and the impact on cell viability was assessed.  (D) 
Cell viability in BRCA proficient mouse mammary tumor organoids treated with either 
verteporfin, cisplatin or the combination was assessed.  Dot plots (mean ± standard 
deviation) represent three independent experiments.  * p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 
















Fig. 3.7.  VEGF-NRP2 controls YAP/TAZ-mediated Rad51 expression and HR.  
Expression of (A) NRP2 and (B) VEGF was diminished in MDA-MB-231 cells and the 
impact on Rad51 abundance was quantified by immunoblotting.  Densitometry was 
assessed using ImageJ (right bar graphs).  (C) VEGF-depleted MDA-MB-231 cells were 
treated with 50 ng/mL of VEGF for 24 hours.  Medium was then replaced, and cells were 
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treated with cisplatin and also 50 ng/mL of VEGF in VEGF-depleted cells.  γH2AX and 
Rad51 abundance was quantified by immunoblotting.  (D) Hs578t DR-GFP cells were 
transfected with Rad51 or empty vector.  Subsequently, they were treated with a control 
IgG or a NRP2 function blocking antibody and processed for flow cytometry to quantify 
GFP positive cells.  GFP positive cells were normalized to 1 and are depicted as HR 
efficiency.  (E) NRP2-depleted Hs578t cells expressing Rad51 or a control vector were 
treated with cisplatin and the impact on cell viability was assessed.  (F) The expression of 
Rad51 was compared with VEGFA and NRP2 in the Metabric database.  Log odds ratios 
were generated and p values were calculated using fisher exact t test.  Dot plots (mean ± 
standard deviation) represent three independent experiments. * p ≤ 0.05, ** p ≤ 0.005, *** 
p ≤ 0.0005 by two-tailed t test.                  
 











Fig. 3.8. VEGF-NRP2 promotes resistance to PARP inhibition and ionizing radiation.   
(A) Expression of NRP2 and VEGF was diminished with shRNAs in MDA-MB-231 cells, 
which were subsequently processed for immunofluorescence microscopy to assess baseline 
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γH2AX.  Scale bar represents 50 µm.  (B) Cell viability in control and NRP2-depleted 
Hs578t cells treated with and without olaparib was assessed.  (C) Cell viability in control 
and NRP2-depleted Hs578t cells treated with the indicated doses of IR was assessed.  (D) 
Hs578t cells were pre-treated with a control IgG or a NRP2 function blocking antibody.  
Subsequently, they were treated with 6 Gy of IR and the impact on γH2AX abundance was 
quantified by immunoblotting 30 minutes following IR.  Dot plot (mean ± standard 






















Fig. 3.9. YAP/TAZ promote homologous recombination by DR-GFP analysis.  (A) 
Representative flow cytometry of MCF7 DR-GFP cells expressing a control vector, S89A 
TAZ or S127A YAP.  (B) Expression of FLAG-tagged S89A TAZ and S127A YAP in 





Fig. 3.10.  Rad51 rescue levels in YAP/TAZ-depleted cells and baseline γH2AX upon 
YAP/TAZ depletion.  (A)  Expression of YAP/TAZ was diminished with siRNA in 
Hs578t cells (siRNA YT).  Cells were then transfected with HA-tagged Rad51 or empty 
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vector and processed for immunoblotting to quantify the degree of Rad51 rescue.  
Densitometry was assessed using ImageJ (right bar graph).  (B)  Expression of YAP/TAZ 
was diminished with siRNA in Hs578t cells, which were subsequently processed for 
immunofluorescence microscopy to assess baseline γH2AX.  Scale bar represents 50 µm.  
(C) Expression of Rad51 was quantified in control and TAZ-depleted MDA-MB-231 cells 
by immunoblotting to determine the degree of Rad51 rescue.  Densitometry was assessed 
















Fig. 3.11.  YAP/TAZ do not regulate DNA damage dynamics in BRCA1 mutant cells.  
Expression of TAZ was depleted in SUM-1315 cells, which were treated with verteporfin 
and cisplatin and processed for (A) immunofluorescence microscopy to assess γH2AX and 
(B) immunoblotting to assess γH2AX and Rad51.  Scale bar represents 50 µm.  Dot plot 






Fig. 3.12.  Rad51 rescues homologous recombination upon NRP2 inhibition by DR-
GFP analysis. (A) Representative flow cytometry of Hs578t cells transfected with empty 
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vector or Rad51 and subsequently treated with a control IgG or a function blocking NRP2 
antibody.  (B) Expression of Rad51 was quantified in control and NRP2-depleted cells by 
immunoblotting to determine the degree of Rad51 rescue.  Densitometry was assessed 

















CHAPTER IV: DISCUSSION 
Overview 
 This thesis has focused on the mechanisms by which autocrine VEGF signaling 
mediated by NRP2 confers CSC properties, DNA repair and resistance to therapy in TNBC 
cells.  The first chapter revealed that VEGF-NRP2 signaling converges on the hippo 
pathway transducers TAZ and YAP by a Rac1-dependent, feed-forward mechanism.  It 
also characterized the Rac GAP β2-chimaerin as a novel target gene repressed by 
YAP/TAZ-TEAD-dependent gene regulation.  Importantly, I discovered that β2-chimaerin 
repression is critical for the acquisition of CSC properties mediated by upstream VEGF-
NRP2-YAP/TAZ signaling.  These observations provide one mechanism that sustains 
enhanced YAP/TAZ activity and CSC properties in breast cancer.  They are also significant 
because they link VEGF, a key component of the tumor microenvironment, with YAP/TAZ 
regulation, which is independent of its function in angiogenesis.  
 In the second chapter of this thesis, I extended my analysis of the VEGF-NRP2-
YAP/TAZ signaling axis to therapy resistance in TNBC cells.  Specifically, I observed that 
VEGF-NRP2-YAP/TAZ promotes resistance to agents that induce DNA damage by 
promoting HR-directed DNA repair.  This mechanism occurs through direct transcriptional 
regulation of the HR recombinase Rad51 by YAP/TAZ-TEAD dependent gene regulation.  
My findings link important characteristics of TNBC: dependence on VEGF-NRP2 
signaling, hyper-activation of YAP/TAZ and high Rad51 mechanism into a mechanism  
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that accounts for its resistance to therapy.  These results are significant because efficient 
HR is an important predictor of TNBC patient response to treatment, and they demonstrate 
that targeting VEGF-NRP2 or YAP/TAZ may lead to more favorable response to platinum 
chemotherapy.  
 
Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and 
cancer biology 
The first section of Chapter IV titled “Convergence of VEGF and YAP/TAZ signaling: 
Implications for angiogenesis and cancer biology” represents a review article previously 
published.  
This work was originally published in Science Signaling. Ameer L. Elaimy and Arthur M. 
Mercurio.  Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis 
and cancer biology.  Science Signaling.  2018 Oct 16;11(552). pii: eaau1165. doi: 
10.1126/scisignal.aau1165.  From Science Signaling. Reprinted with permission from 
AAAS.   
 
CONTRIBUTIONS: 






Vascular endothelial growth factor (VEGF) was identified and isolated as an 
endothelial cell-specific mitogen that has the capacity to induce developmental and 
pathological angiogenesis (34, 35).  More recent work has revealed the ability of VEGF to 
target tumor cells, especially cells with stem-like traits, referred to as cancer stem cells 
(CSCs) and, consequently, contribute to tumor initiation, progression, and recurrence 
directly (42).  These vital functions of VEGF are mediated by specific receptors expressed 
on endothelial and tumor cells including receptor tyrosine kinases (VEGFR1 and 
VEGFR2) and the neuropilins (NRPs), which function as VEGF co-receptors (52, 62, 117, 
118, 197).  The mechanisms by which these VEGF receptors execute these diverse 
functions are of paramount importance because of their potential as therapeutic targets.  
Not surprisingly, VEGF-mediated signaling events have been studied intensely but much 
remains to be learned.  In particular, a better understanding of how VEGF signaling impacts 
the cell biology that underlies vascular growth and remodeling (angiogenesis) and self-
renewal (CSCs) is needed.  In this direction, recent work has uncovered a convergence of 
VEGF and Hippo signaling that has the potential to provide considerably new insight into 
angiogenesis and CSC function.    
The Hippo pathway is critical for development because it restricts proliferation and 
controls organ size (198).  Inhibition of this pathway results in the activation of YAP and 
TAZ, transcriptional co-activators that have profound effects on cell behavior.  Active YAP 
and TAZ reside in the nucleus where they associate with the TEA domain (TEAD) family 
of transcription factors and regulate the expression of numerous target collectively known 
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as a YAP/TAZ “signature”.  Several cues, such as high cell density and polarity, can 
activate the core Hippo tumor suppressor pathway and thereby inhibit YAP/TAZ.  This 
pathway consists of a kinase cascade mediated by the MST 1/2 kinases, which 
phosphorylate and activate the LATS 1/2 kinases (146).  Activated LATS 1/2 directly 
phosphorylates YAP/TAZ at several conserved residues, with serine 127 of YAP and serine 
89 of TAZ being the classical and most heavily studied LATS 1/2 phosphorylation sites.  
YAP/TAZ phosphorylation creates 14-3-3 binding sites, which results in their cytoplasmic 
retention, separation from the TEAD family of transcription factors, and functional 
inactivation (91, 146).  In addition to core MST/LATS kinase Hippo signaling, YAP/TAZ 
activity can be controlled by several other molecular factors termed the “extended” Hippo 
pathway.  Although the core Hippo pathway and its extended components are well-
characterized (89), a rigorous understanding of signaling at the cell surface that leads to 
inactivation of the Hippo pathway and contributes to enhanced YAP/TAZ activity is still 
emerging.  What has been shown recently is that VEGF receptor signaling can repress the 
Hippo pathway resulting in YAP/TAZ activation.  The essence of these findings is that 
VEGF signaling impacts Rho family GTPase activity and cytoskeletal dynamics, which 
contribute to YAP/TAZ activation, and that YAP/TAZ-mediated transcriptional changes 
sustain GTPase activity and cytoskeletal dynamics to affect vascular growth and 
remodeling in endothelial cells and the acquisition of stem-like traits in tumor cells (Figure 
4.1).  These findings are significant because of their pathophysiological importance and 
their connection to other receptor-mediated pathways.  This review discusses these findings 
and highlights areas for future study.     
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YAP/TAZ as Effectors of VEGF Signaling in Developmental Angiogenesis 
The vascularization of tissues during development is a precisely orchestrated 
angiogenic process mediated primarily by VEGF that involves endothelial cell 
proliferation and survival, loss of cell-cell contacts, basement membrane degradation and  
directed migration (199).  These diverse functions of endothelial cells are mediated, in part, 
by transcriptional and cytoskeletal alterations, but the mechanisms responsible for these 
alterations are still being elucidated.  For this reason, the initial report describing VEGF-
mediated YAP/TAZ activation in promoting developmental angiogenesis was a significant 
advance (171).  More specifically, this study observed VEGF-mediated YAP/TAZ 
activation in a variety of endothelial cells in vitro.  They also performed endothelial-cell 
specific deletions of YAP/TAZ and demonstrated their importance in embryonic and 
postnatal vascular development.  YAP/TAZ deletion resulted in an impaired vascular 
response to VEGF indicating that YAP/TAZ are important regulators of angiogenesis 
downstream of VEGF.  The mechanism by which VEGF activates YAP/TAZ in endothelial 
cells involves VEGFR2 activation of Src family kinases and subsequent cytoskeletal 
rearrangements mediated by Src activation of Rho family GTPases.  Inhibiting VEGF-
VEGFR2-Src-Rho GTPase signaling promoted LATS-mediated YAP/TAZ 
phosphorylation, which is consistent with reports that the generation of mechanical tension 
by Rho GTPases inhibits LATS kinases and activates YAP/TAZ (89, 102, 103, 136).    This 
study also uncovered a positive feedback loop enabled by YAP/TAZ-dependent 
transcriptional alterations that sustains cytoskeletal alterations and Rho GTPase activity.  
More specifically, chromatin immunoprecipitation sequencing (ChIP-Seq) analysis 
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revealed that VEGF-VEGFR2-Src-Rho GTPase signaling promotes YAP/TAZ dependent 
expression of several cytoskeletal remodeling genes, including Myosin 1C  (171).  This 
finding is significant because Myosin 1C has been implicated in VEGFR2 trafficking from 
the Golgi apparatus to the plasma membrane (200).  Consequently, enhanced YAP/TAZ 
activity was shown to be critical in retaining VEGFR2 on the cell surface and promoting a 
feedforward loop sustaining VEGF-VEGFR2-Src-Rho family GTPase activation of 
YAP/TAZ that contributes to developmental angiogenesis.  In this direction, YAP/TAZ 
have been reported to activate the Rho GTPase Cdc42 as a mechanism of endothelial cell 
migration in angiogenesis.  There is conflicting evidence, however, whether YAP/TAZ 
regulate Cdc42 expression and activity directly (201) or by an indirect mechanism (202).  
Nonetheless, these studies highlight a critical function of YAP/TAZ in the regulation of 
Rho family GTPases and cytoskeletal dynamics in the context of endothelial cell function.  
The more novel finding that is emerging from this work is that VEGF may be a key 
regulator of these processes.         
Other studies have independently established that LATS kinases are regulated by 
upstream VEGF-Rho GTPase signaling in endothelial cells (203).   Inhibitors of VEGFRs 
were identified as enhancers of LATS kinase activity using a novel bioluminescence-based 
biosensor to monitor LATS kinase activity in response to treatment with a small molecule 
kinase inhibitor library (204).   This screen prompted the analysis and validation of VEGF-
VEGFR2-mediated LATS inhibition and YAP/TAZ activation in in vitro and in vivo 
angiogenesis assays.  Together, the studies described reveal a casual role of VEGF-
mediated YAP/TAZ activation in developmental angiogenesis by mechanisms that 
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modulate LATS kinase activity, and they highlight the critical involvement of Rho family 
GTPases and the cytoskeleton.  It is important to note that other studies had implicated 
Hippo signaling in angiogenesis (205), but they did not assess the potential role of VEGF 
signaling in regulating this pathway.  This issue is timely because a recent study implicated 
BMP signaling and discounted the involvement of VEGF in YAP/TAZ regulation of 
sprouting angiogenesis in the mouse retina (107).  Clearly, more work is needed to define 
the contribution of VEGF signaling to YAP/TAZ activation in developmental angiogenesis 
and to assess its relationship to other signaling pathways.  
 
Role of VEGF-mediated YAP/TAZ Activation in Cancer Stem Cells 
The seminal finding that VEGF-mediated angiogenesis is a hallmark of cancer 
sparked intense interest in the identification of signaling pathways in tumor-associated 
endothelial cells that are driven by VEGF and how they can be exploited for therapeutic 
purposes (44).   To date, YAP and TAZ have not been implicated in tumor angiogenesis, 
although such a role seems likely given the data described above on developmental 
angiogenesis.  Another significant contribution of VEGF-mediated YAP/TAZ activation 
involves tumor cells themselves.  More specifically, autocrine VEGF signaling has 
emerged as an essential pathway for many CSCs and the NRPs appear to play a major role 
in mediating this signaling (42).  CSCs are defined as a subpopulation of cells that exhibit 
properties of stem cells including self-renewal and function in tumor initiation, 
differentiation into heterogeneous cancer cell lineages, and therapy resistance.  The role of 
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VEGF signaling mediated by the NRPs in sustaining self-renewal and CSC functions has 
been demonstrated for several types of cancer (42).  Moreover, the hypothesis that VEGF-
NRP signaling sustains CSCs has significant implications for therapy because the most 
common anti-VEGF drug (bevacizumab) blocks the binding of VEGF to receptor tyrosine 
kinases but not to NRPs (2).  This observation may explain, in part, the dismal efficacy of 
bevacizumab for many cancers (206, 207), and it highlights the potential benefit of 
targeting the NRPs directly.  For this reason, understanding how VEGF-NRP signaling 
impacts CSCs is a timely and significant problem.  Studies in this area have focused largely 
on breast cancer based, in part, on reports that enhanced TAZ activity is associated with 
high-grade breast tumors and the function of breast CSCs (111), and our finding that 
autocrine VEGF signaling mediated by NRP2 confers stem cell-like traits in breast cancer 
(68).  In light of this information, we sought to identify the mechanism involved and 
discovered that autocrine VEGF-NRP2 signaling promotes the self-renewal of breast CSCs 
by sustaining TAZ activation (63).  The significance of this observation is that it integrates 
VEGF signaling with TAZ activation as a mechanism that underlies CSC function.  Our 
pursuit of how VEGF activates TAZ revealed a key role for the Rho GTPase Rac1.  More 
specifically, we observed that VEGF-NRP2 signaling promotes focal adhesion kinase 
(FAK)-mediated Rac1 activation.    
One mechanism by which Rac1 contributes to TAZ activation involves p21-
activated kinase (PAK), a Rac-activated kinase, that phosphorylates Merlin, the protein 
encoded by the Neurofibromatosis Type 2 gene, on Ser518 (147-149).  This 
phosphorylation inhibits LATS phosphorylation (89, 97-99) and, consequently, facilitates 
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YAP/TAZ activation (63, 208).  Consistent with these findings, we found that either Rac 
inhibition or NRP2 depletion in CSCs reduced the abundance of Ser518-phosphorylated 
Merlin and LATS-mediated phosphorylation of TAZ at Ser89 (63).  This information, 
combined with the studies discussed above, highlights a critical role of Rac1 in YAP/TAZ 
activation by potentially eliciting a “dual hit” on LATS, through its regulation of the 
cytoskeleton and facilitating Merlin phosphorylation.     
By profiling the expression of Rac1 guanine nucleotide exchange factors (GEFs) 
and GTPase activating proteins (GAPs) in CSCs and non-CSCs, we found that the 
expression of the Rac-specific GAP β2-chimaerin was significantly reduced in CSCs 
compared to non-CSCs.  This led to our hypothesis that β2-chimaerin repression is a 
consequence of TAZ-dependent gene regulation, which is sustained by upstream VEGF-
NRP2-Rac1 signaling.  The functional significance of β2-chimaerin repression was 
demonstrated by depleting β2-chimaerin in non-CSCs and observing enhanced TAZ 
activity and CSC properties.  Importantly, we identified an inverse correlation in the 
expression of TAZ with β2-chimaerin and positive correlations in the expression of TAZ 
with VEGF and NRP2 in human breast tumors.  Although β2-chimaerin has been identified 
as a tumor suppressor in breast cancer (153-155), mechanisms of its transcriptional 
regulation had not been reported.  As a result, our study characterized a positive feedback 
loop in breast CSCs where Rac1 functions as a nexus that connects VEGF-NRP2 signaling 
to TAZ activation by a mechanism that involves TAZ-dependent repression of the Rac 
GAP β2-chimaerin.               
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Interestingly, VEGF-mediated YAP/TAZ activation in CSCs appears to be 
mediated by NRPs and it does not seem to involve VEGFRs (63, 209), which distinguishes 
it from VEGF activation of YAP/TAZ in endothelial cells described above.  This 
conclusion is substantiated by other studies in breast and prostate cancer cells, which 
argued that VEGF-NRP-mediated Rac1 activation is VEGFR-independent (63, 64).  Given 
that NRPs function as co-receptors and lack intrinsic signaling properties (56, 57, 210), the 
issue of how NRPs activate YAP/TAZ arises.  One mechanism involves the ability of 
NRP2 to function as a co-receptor for the α6β1 integrin.  We reported that this integrin 
associates with NRP2 in breast cancer cells and that this interaction facilitates the signaling 
potential of this integrin, including its ability to activate FAK (68, 73), which is consistent 
with the report that VEGF-NRP2 activates Rac1 in a FAK-dependent manner (63).  A more 
recent study confirmed the importance of NRPs in regulating α6 integrin signaling in 
epidermal CSCs and the lack of VEGFR involvement (209).  More work is needed, 
however, to exclude the involvement of VEGFRs in VEGF-mediated YAP/TAZ activation 
definitively, especially in light of their key role in YAP/TAZ activation in endothelial cells.  
Other work by our group refined the role of α6β1 signaling in sustaining CSC 
function by demonstrating that a cytoplasmic domain splice variant of the α6β1 integrin, 
termed α6Bβ1, promotes breast CSC function through downstream TAZ activation (129).  
In contrast, the other splice variant, α6Aβ1, lacks this ability.  We also showed that the 
engagement of α6Bβ1 with a specific laminin in the extracellular matrix, laminin 511, is 
required for its ability to activate TAZ.  This finding raises the important issue of the role 
of the extracellular matrix (ECM) in VEGF-mediated YAP/TAZ activation.  Given that 
111 
 
this activation appears to be dependent on cytoskeletal dynamics and mechanical tension, 
the ECM is likely to be critical, as is the involvement of specific integrins as we have shown 
for laminin 511-α6Bβ1.  Indeed, the role of ECM and integrins in VEGF-mediated 
YAP/TAZ activation is an area that is ripe for investigation for angiogenesis and CSC 
function.  In the latter case, the concept of a CSC niche has emerged comprised of non-
CSCs and ECM proteins that supports CSC function (211, 212).  In fact, we identified 
laminin 511 as a component of this niche in breast cancer (129).  Much more work needs 
to be done, however, to understand how ECM-integrin signaling functions in concert with 
VEGF signaling to impact YAP/TAZ activation.   More than likely, other surface receptors 
are also involved in this process.  
 
Concluding Comments 
 The role of YAP/TAZ activation in executing the functional consequences of 
VEGF signaling in endothelial and CSCs that has become apparent is providing new insight 
into the mechanisms that underlie angiogenesis and the acquisition of stem-like traits.  A 
central theme that has emerged from these studies is the critical role of the Rho family of 
small GTPases in mediating the signaling events initiated by VEGF to activate YAP/TAZ.  
These GTPases contribute to YAP/TAZ activation indirectly by altering cytoskeletal 
dynamics (mechanical tension) and directly by inhibiting LATS phosphorylation.  The 
transcriptional alterations that result from YAP/TAZ activation can initiate a positive 
feedback loop that sustains Rho GTPase activation and mechanical tension.  Although 
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aspects of this signaling network had been established previously, the novelty of the recent 
studies highlighted in this review is the ability of VEGF and VEGF receptors to orchestrate 
this network.  This mode of YAP/TAZ regulation is significant because VEGF signaling 
itself is tightly regulated during development and aberrantly activated by the tumor 
microenvironment, which provides a pathophysiological context for YAP/TAZ activation.   
 Looking forward, a better understanding of how the different types of VEGF 
receptors (receptor tyrosine kinases and NRPs) contribute to YAP/TAZ activation and their 
interaction with other surface receptors is needed.  These studies should consider the role 
of the ECM and tissue microenvironment in VEGF receptor signaling (Figure 4.1).  Other 
areas ripe for investigation that are depicted in Figure 4.1 include delineating the specific 
contributions of different Rho GTPase family members to YAP/TAZ activation in the 
context of VEGF signaling.  Also, much more needs to be learned about how YAP and 
TAZ affect gene expression to execute VEGF-mediated functions in endothelial and tumor 
cells and how YAP and TAZ may differ in this regard.  The impact of this work is likely 
to be substantial given the intense interest in targeting VEGF signaling as a therapeutic 





















Figure 4.1.  Schematic of VEGF and YAP/TAZ signaling thus far described in 
endothelial and tumor cells.  Emerging studies suggest that VEGF signaling mediated by 
VEGFR2 and/or NRPs increases the activity of Rho family GTPases, resulting in LATS 
inhibition and YAP/TAZ activation, with consequent promotion of angiogenesis and stem 
cell maintenance. Integrins have a key role in this signaling by associating with NRPs and 
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engaging the extracellular matrix (ECM). VEGF signaling can involve Src-mediated Rho 
activation and the consequent activation of YAP/TAZ through cytoskeletal dynamics. It 
can also inhibit LATS by a Rac1-dependent mechanism that involves p21-activated kinase 
(PAK)–mediated inhibition of Merlin. An important question is whether these two 
mechanisms function in concert to promote YAP/TAZ activation in response to VEGF 
signaling. YAP/TAZ-mediated transcription can alter the expression of genes involved in 
cytoskeletal remodeling and in Rho and Rac1 activation, such as through the transcriptional 
repression of Rac GTPase activating proteins (GAPs) that normally turn off Rac, thereby 













Role of the VEGF-NRP2-YAP/TAZ axis in DNA repair and therapy resistance 
 In the second study of this thesis, I established that autocrine VEGF-NRP2 
signaling contributes to HR-directed repair in BRCA-wild type TNBC cells by contributing 
to the expression and function of the HR recombinase Rad51.  Importantly, I identified 
Rad51 as a novel target gene of YAP/TAZ-TEAD-mediated transcriptional regulation.  
These findings are substantial because they integrate the VEGF-NRP2-YAP/TAZ 
signaling axis, discussed above, with HR-directed repair and therapy resistance.  My 
findings implicating VEGF-NRP2-YAP/TAZ in DNA repair have potentially substantial 
implications for cancer biology and therapy.  
 Targeting VEGF-mediated signaling mechanisms in cancer is not a new idea.  In 
fact, bevacizumab, the first VEGF inhibitor was approved by the Food and Drug 
Administration (FDA) for the treatment of breast cancer in 2004 (213).  The rationale in 
inhibiting the function of VEGF was based on disrupting angiogenesis mediated by VEGF-
VEGFR signaling in tumor-associated endothelial cells (214).  By disrupting this key 
endothelial signaling axis, it was postulated that the reduction in oxygen and nutrient 
transportation to the tumor would contribute to inhibiting its growth.  Following the 
approval of bevacizumab, several small molecule inhibitors of VEGFRs were developed 
that have shown favorable outcomes in several other tumor types including renal cell 
carcinoma, gastrointestinal tumors and hepatocellular carcinoma, among others (215).  
Surprisingly, although bevacizumab showed promise in the initial clinical trials that led to 
its approval, the FDA discontinued its label for the treatment of breast cancer in 2011 due 
to a lack of efficacy (1).  This decision sparked intensive research into the mechanisms that 
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contribute to resistance to anti-angiogenic therapy and how this information can be 
incorporated into clinical decision making.  
 The seminal finding that my thesis builds on is that cancer cells express VEGF 
receptors, which can impact oncogenic processes independently of vascular biology.  
Given that cancer cells express NRPs in addition to VEGFRs, several studies have analyzed 
the potential contribution of autocrine and paracrine VEGF-NRP signaling in resistance to 
anti-angiogenic agents as well as other therapies.  Consistent with my work that Rac1 is a 
key mediator of VEGF-NRP2 signaling in breast cancer cells, another study in prostate 
cancer demonstrated that VEGF-NRP2-Rac1 signaling promotes resistance to 
bevacizumab and VEGFR inhibitors (124).  Specifically, prostate cancer cells selected for 
resistance to these agents exhibited CSC properties and up-regulation of VEGF and NRP 
expression, as well as enhanced Rac1 activity.  The mechanism by which VEGF-NRP2 
promotes resistance to anti-VEGF therapy is through downstream activation of 
extracellular regulated kinase (ERK), which subsequently facilitates expression of the 
Rac1 GEF P-rex1.  This induction of P-rex1 occurs through ERK-mediated activation of 
Myc.  Interestingly, P-rex1 is not expressed in TNBC (216), suggesting different 
mechanisms of VEGF-NRP2 activation of Rac1 that are tumor-type dependent.  
Nonetheless, these findings are significant because they directly implicate VEGF-NRP2-
Rac1 signaling in resistance to anti-VEGF-VEGFR therapy and highlight this signaling 
axis as a potential therapeutic target in prostate cancer. 
 Consistent with the above report that NRP2 is upregulated in the adaptive resistance 
of tumor cells to therapy, another study demonstrated a key role for NRP1 in resistance to 
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targeted therapy (190).  Specifically, NRP1 expression increases in melanoma cells 
resistant to BRAF inhibition and breast cancer cells resistant to HER2 inhibition.  
Enhanced NRP1 signaling contributed to c-jun N-terminal kinase (JNK) activation and 
subsequent upregulation of the epidermal growth factor receptor (EGFR) and insulin-like 
growth factor 1 receptor (IGF-1R), which sustained tumor cell growth and resistance.   
 The above studies characterizing NRPs in resistance to anti-VEGF and oncogene-
targeted therapy provide important insight into their evolving role in tumor biology.  
However, VEGF-NRP signaling has not been implicated in resistance to DNA-damaging 
agents such as cytotoxic chemotherapy and radiation therapy, which are standards of care 
in most tumor types.  It follows that determining mechanisms to overcome this resistance 
by targeting DNA damage pathways are being actively explored (217).  My work 
implicating VEGF-NRP2 signaling in HR is novel and identifies this molecular association 
in resistance to commonly used anti-cancer therapies.  This work provides rationale for 
further translational research integrating inhibitors of VEGF-NRP2 signaling with standard 
chemoradiation therapy regimens.  This point is exemplified by my work in TNBC cells 
and organoids because efficient HR is a key determinant of TNBC patient therapeutic 
responses and disrupting VEGF-NRP2 signaling can sensitize to platinum chemotherapy, 
PARP inhibition and ionizing radiation.  
 Studies have reported that VEGF expression and secretion increases in the response 
of tumor cells to ionizing radiation and is associated with aggressive behavior (218, 219).  
My work establishing a function of autocrine VEGF-NRP2 signaling in HR has potentially 
important applications stemming from the observation that VEGF is upregulated in the 
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tumor microenvironment following radiation therapy.  This is because enhanced VEGF-
NRP2-mediated activation of YAP/TAZ and subsequent Rad51 expression in response to 
radiation is likely to promote resistance by stimulating HR.  Therefore, regarding my point 
above about translational research integrating inhibitors of VEGF-NRP2 signaling with 
chemoradiation, it would be critical to study the kinetics of blocking NRP2 function.  The 
reason for this is that combined inhibition of NRP2 with radiation and/or blocking NRP2 
for a time period after radiation may lead to more favorable patient responses by disrupting 
the autocrine signaling mediated by enhanced VEGF in the tumor microenvironment.    
Another major advance of my work is characterizing a role for YAP/TAZ in HR by 
regulating the expression of Rad51.  Although YAP/TAZ have been implicated in the 
initiation and progression of breast and other cancers (110, 111), their contribution to DNA 
repair has not been previously reported, and my results and define a novel function of these 
transcriptional effectors.  This finding is especially significant because YAP/TAZ have 
been implicated in therapy resistance, similar to VEGF-NRP2, but satisfying mechanisms 
have remained elusive (110).  Given that YAP/TAZ confer CSC properties in TNBC, 
which have been implicated in tumor initiation, therapy resistance and recurrence (120-
123), future work should focus on the role of Rad51 in CSCs and determining if CSCs 
exhibit more efficient HR than non-CSCs in response to therapy.  This possibility is 
supported by my finding that YAP/TAZ contributes to Rad51 expression suggesting that 
breast CSCs, which are dependent on a YAP/TAZ transcriptional program, upregulate 
Rad51 as a mechanism of protecting themselves from genotoxic stress in order to preserve 
genomic integrity and facilitate long-term survival.  These observations are consistent with 
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studies demonstrating that CSCs exhibit a more robust DNA damage response than non-
CSCs in response to therapy (220).  My findings integrating YAP/TAZ with Rad51 and 
HR provides a new dimension to our understanding of the critical role they play in breast 
cancer oncogenesis and, possibly, CSC survival and propagation following treatment with 
chemo- and radiation therapy.        
Concluding remarks 
My thesis work provides a mechanism by which autocrine VEGF signaling 
mediated by its non-canonical receptor NRP2 promotes CSC properties, DNA repair and 
therapy resistance in TNBC cells.  Specifically, in the first part of my thesis, I characterized 
a previously unknown positive feedback circuit by which VEGF-NRP2 signaling 
converges on YAP/TAZ.  In pursuit of this mechanism, I demonstrated a critical role for 
the Rac1 GTPase in mediating VEGF-NRP2 signaling to YAP/TAZ.  Importantly, I 
discovered that the Rac GAP β2-chimaerin is a novel target gene that YAP/TAZ-TEAD 
represses to sustain enhanced Rac1 activity.  These findings could have a profound impact 
in VEGF and YAP/TAZ biology by providing a targetable ligand-receptor association that 
contributes to enhanced YAP/TAZ activity.  Additionally, subsequent studies have later 
revealed that Rho family GTPase GAPs can be regulated by and inhibit the functions of 
YAP/TAZ, which is consistent with my work that low β2-chimaerin expression is critical 
for YAP/TAZ activation (146).   
The second part of my thesis extended the findings of Chapter II assessing the 
contribution of VEGF-NRP2-YAP/TAZ signaling in the response of TNBC cells to HR-
inducing therapy.  I identified novel functions of VEGF-NRP2 and YAP/TAZ in DNA 
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repair by demonstrating that they converge on Rad51 to promote efficient HR and therapy 
resistance in BRCA-wild type TNBC cells and organoids.  This work also provides one of 
the first mechanisms governing Rad51 transcription, which is an area that is poorly 
understood.  Together, my findings demonstrate a unified mechanism by which VEGF-
NRP2-YAP/TAZ contributes to the aggressive behavior and therapy resistance of TNBC. 
My findings have potentially substantial therapeutic implications.  This is because 
targeting YAP/TAZ has been a challenge, and their inhibition has potential to disrupt 
physiological processes such as organ homeostasis.  In addition, although Rad51 inhibitors 
exist, they can result in considerable toxicity because Rad51 has important housekeeping 
functions in DNA repair and replication.  Given that NRP2 is preferentially expressed in 
tumors and contributes to hyper-activation of YAP/TAZ and high Rad51 expression, its 
inhibition may provide the selectivity needed to specifically disrupt the YAP/TAZ-Rad51 
axis in cancer.  Further translation research is of utmost importance to determine the 
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The ability to monitor changes in the expression and localization of specific 
integrins is essential for understanding their contribution to development, tissue 
homeostasis and disease.  Here, we pioneered the use of Crispr/Cas9 genome editing to tag 
an allele of the 4 subunit of the 64 integrin.  This integrin was chosen because of its 
diverse roles in epithelial and cancer biology.  A tdTomato tag was inserted with a linker 
at the COOH-terminus of 4 in comma-d1 mouse mammary epithelial cells.  Cells 
harboring this tagged allele were similar to wild-type cells with respect to the abundance 
of 4 on the cell surface, association of 4 with the 6 integrin subunit, as well as their 
ability to adhere to laminin and, consequently, activate Src.  These 4 reporter cells were 
transformed with active YAP, which resulted in repression of 4 expression.  The 
availability of control and YAP-transformed reporter cells enabled us to obtain novel 
insight into 4 dynamics in response to a migratory stimulus (scratch wound) by live-cell 
immunofluorescence video microscopy.  Notably, an increase in 4 expression in cells 
proximal to the wound edge was evident and a population of 4 expressing cells that 
exhibited unusually rapid migration was identified. These findings that could shed insight 
into 4 dynamics during invasion and metastasis. Moreover, these 4 reporter cells should 







Changes in the expression and localization of specific integrins underlie the 
contribution of these receptors to a wide range of biological and pathological processes 
(221-224).  The monitoring of these changes in real-time facilitates rigorous evaluation of 
their significance and functional contribution.  The challenge to this approach, however, is 
preserving integrin function and cell homeostasis.  For this reason, genome editing of 
integrins with Crispr/Cas9 technology has considerable potential.  Although techniques 
describing integrin tagging have been previously described (225-228), Crispr/Cas9 genomic 
engineering to knock-in fluorescent tags has not been used for this purpose.  This approach 
is ripe for employment because it allows direct visualization of the integrin transcribed from 
the endogenous gene and it circumvents the use of ectopic expression systems that have the 
potential for artifact.  Given the challenges of monitoring integrins in real-time, the use of 
this technology to study their plasticity is timely and could be a useful resource for cell 
biologists.    
A prime candidate for genome editing is the 64 integrin (referred to as ‘4’ 
because there is only one 4 integrin).  This integrin functions as a receptor for most 
laminins and it is expressed at the basal surface of many epithelial tissues (229, 230). The 
distinguishing structural feature of 4 is the atypical intracellular domain of the 4 subunit, 
which is distinct both in size (~1000aa) and structure from any other integrin subunit (231).   
A major function of this intracellular domain is to link 4 to intermediate filaments in stable 
adhesive structures termed hemidesmosomes (HDs) (232, 233).  Our lab pioneered studies 
demonstrating that 4 has a more dynamic role in promoting cell migration and invasion 
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(234-236).  Specifically, we discovered that 4 is mobilized from HDs in response to 
epithelial wounds or as a consequence of carcinoma progression and that it localizes in F-
actin protrusions where it facilitates migration and invasion (237-242).  Subsequent studies 
have confirmed and extended these findings e.g., (243, 244).  These conclusions, however, 
were based primarily on immunofluorescence microscopy of fixed cells using 4-specific 
Abs and not real-time imaging of 4 in live cells.  This consideration is significant because 
the published data suggest that rapid changes in 4 expression and localization may occur 
as cells acquire the ability to migrate.       
In this Tools and Resources study, we used Crispr/Cas9-mediated homologous 
donor recombination (HDR) to knock-in a tdTomato tag to the cytoplasmic domain of the 
β4 integrin in mouse mammary epithelial cells.  Oncogenic transformation of these cells 
with YAP enabled real-time monitoring and comparison of β4 expression and localization 
in live, normal and transformed epithelial cells in response to a scratch wound.      
 
Results 
Design and approach for Crispr/Cas9-mediated integrin β4 tagging:  
We designed a strategy to knock-in a tdTomato tag connected by an 8 amino acid linker to 
the COOH-terminus of mouse integrin β4 using Crispr/Cas9-mediated homologous donor 
recombination (HDR).  Our approach was based on limiting the likelihood of the 
endogenous tag altering β4 function, which includes laminin binding extracellularly and 
β4 signaling intracellularly.  To accomplish this goal, we inserted the tdTomato tag 
connected by a linker at the COOH-terminus (cytoplasmic domain) near the last exon of 
125 
 
β4 because it ensures that the tag will not interfere with laminin binding extracellularly.  
The purpose of the linker was to provide space between β4 and the fluorescent tag to limit 
disruption of β4 interactions with cytoplasmic molecules.     
Our initial step was to design, test the cutting efficiency and the effects on β4 
expression of four sgRNAs targeting the region of the last exon of mouse integrin β4.  Our 
goal in choosing a sgRNA and designing a corresponding donor plasmid was to identify a 
sgRNA that exhibits the greatest cutting efficiency and does not alter β4 expression.  As 
shown in Fig. A.1A, none of the four sgRNAs we tested reduced β4 surface abundance 
when compared to a non-target sgRNA.  This result can be explained because the sgRNAs 
we designed correspond to the region of the last exon of β4, as opposed to Crispr/Cas9 
gene knockout which typically targets one of the first exons of a gene.  We ultimately chose 
sgRNA #2 because it exhibited the greatest cutting efficiency by Tracking of Indels by 
Decomposition (TIDE) analysis (Fig. A.1B), which is a quantitative Sanger sequencing 
assessment that determines the nature and degree of targeted mutations (245).  sgRNA #2 
targets a component of the TGA stop codon and cuts 3 base pairs after the stop codon (Fig. 
A.1C).  Therefore, one consideration in the design of the donor plasmid that corresponds 
to sgRNA #2 is to avoid Cas9 cutting the endogenous locus after HDR has occurred.  To 
accomplish this goal, we introduced silent mutations in the component of the stop codon 
of the sgRNA (TGA to TAA) and the protospacer adjacent motif (PAM), which also 
consists of a component of the last codon (threonine) of β4 (ACC to ACG) (Fig. A.1C).  
We designed 900 base pair left and right homology arms in the donor plasmid based on a 
high recombination efficiency observed in prior studies (246).  The linker sequence 
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(GGSGGSGG) was placed directly upstream of tdTomato, and we inserted a blasticidin 
resistance gene in the donor plasmid because the sgRNA #2/Cas9 plasmid contains a 
puromycin resistance gene.       
Validation of the correct genomic insert in mammary epithelial cells: 
Following the design of the donor plasmid that corresponds to sgRNA #2, we co-
transfected circular donor and sgRNA/Cas9 plasmids into comma-d1 cells, which are 
mouse mammary epithelial cells (247, 248) that express β4.  After 72 hours, we analyzed 
tdTomato expression by flow cytometry and observed that cells transfected with 
donor/sgRNA/Cas9 exhibited 1.2% tdTomato positive cells compared to control cells 
transfected with donor only (Fig. A.1D), which is a similar number of fluorescent cells 
observed using other Crispr/Cas9 knock-in strategies (249).  Of note, we also transfected 
linearized donor plasmid with sgRNA/Cas9 but did not obtain any positive clones.  
We subsequently performed a single-cell sort for tdTomato positive cells and grew 
surviving clones for the next 2-3 weeks to screen for the correct genomic insert.  Clones 
were initially screened by polymerase chain reaction (PCR) amplification of the junction 
between β4 genomic DNA and the left homology arm using the donor plasmid as a negative 
control (Fig. A.1E).  Amplification of the regions between the left homology arm and 
tdTomato, and the right homology arm and tdTomato was performed using the donor 
plasmid as a positive control (Fig. A.1E).  The heterozygous tdTomato tagged β4 allele 
was verified by immunoblotting (Fig. A.1F).  β4 reporter comma-d1 cells were 80% 
positive for tdTomato (Fig. A.1G), which is greater than other studies reporting between 
22 and 76% positive cells using alternative Crispr/Cas9 knock-in strategies (249).  
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Integrin β4 reporter cells retain properties of parental cells:  
 After validation of the correct genomic insert, we evaluated the potential effect of 
the tdTomato tag on the function of β4.  The comma-d1 reporter and parental cells exhibit 
similar levels of β4 at the cell surface indicating that the COOH-terminal tdTomato tag did 
not alter β4 trafficking and surface localization (Fig. A.2A).  The tdTomato tag also did 
not interfere with integrin α6 pairing (Fig. A.2B).  Importantly, the reporter and parental 
cells did not differ significantly in their ability to adhere to laminin111 (Fig. A.2C) and, 
consequently, activate Src (Fig. A.2D), which is an effector of β4-mediated signaling (250, 
251).        
 Comma-d1 cells exhibit mammary progenitor potential (247, 252, 253), and we 
did not observe differences in the number of mammospheres between the reporter and 
parental cells indicating that progenitor properties are not altered in the β4 reporter cells 
(Fig. A.2E).  Together, these data suggest that cyto-tagging β4 using Crispr/Cas9 does not 
alter its function.  They also indicate that the resulting reporter cells are similar in nature 
to parental comma-d1 cells and that our strategy limited potential off-target effects related 
to Crispr/Cas9 genomic alterations.        
Real-time visualization of the expression and localization of the β4 integrin in migrating 
cells: 
The generation of a β4 reporter cell line provided an opportunity to visualize β4 
expression and localization in real-time by immunofluorescence video microscopy.  Given 
the established role of β4 in cell migration, a scratch wound was made in the monolayer 
immediately before filming. A burst of β4 expression was observed approximately 6 hours 
following wounding, especially in cells at the wound edge concomitant with an increase in 
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chemokinetic migration (Fig. A.3; Movies 1,2).  However, there was little evidence of 
directional migration to heal the wound.  
 Based on the fact that the oncogenic transformation of epithelial cells stimulates 
their migration,  we transformed our reporter cell line with YAP, which is a transcriptional 
effector of the Hippo tumor suppressor pathway that has been implicated in breast cancer 
progression, stemness, epithelial to mesenchymal transition (EMT) and drug resistance 
(110, 113, 254-257).   More specifically, we used a constitutively active form of YAP 
(5SA) to transform the comma-d1 reporter cells.  This transformation increased the 
expression of YAP target genes ANKRD1 and Cyr61 (Fig. A.4A,B), promoted soft agar 
colony growth (Fig. 4C) and increased mammosphere number (Fig. A.4D).  Interestingly, 
YAP transformation decreased β4 mRNA expression (Fig. A.4E), and it reduced β4 
surface abundance markedly (Fig. A.4F).   
Immunofluorescence video microscopy of YAP-transformed reporter cells in 
response to a scratch wound revealed directional migration of cells into the scratch by 3 
hours and restoration of the monolayer within 18 hrs of wounding (Fig. 5; Movies 3-6).  
We were able to detect several noteworthy aspects of β4 expression and localization 
because of our ability to visualize endogenous integrin in real-time.  The most striking 
observation was an induction of the β4/tdTomato signal in cells proximal to the wound 
edge, which was evident within 3 hrs of wounding.   Given that YAP transformation 
represses β4 (Fig. A.4E, F), this observation implies that that the migratory stimulus 
imposed by the wound is sufficient to induce expression of this integrin.  It also appeared 
that the induction of β4 expression was coincident with the acquisition of motility in 
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multiple cells.  As the wounds healed and the monolayer was restored, the β4/tdTomato 
signal diminished.  Another key observation was the dynamic polarization of β4 signal at 
the leading edge of cells, which is consistent with its role in driving migration.  Although 
it was not feasible to quantify the velocity of individual cells because of the heterogeneity 
of the population and the number of tdTomato-positive cells, it was evident from observing 
the videos that the tdTomato cells exhibited rapid directional migration and that some of 
these cells migrated across the monolayer extremely quickly relative to migrating 
neighboring cells (See arrows in Fig. A.5; Movies 3-6).     
Discussion 
 The results of this study demonstrate the usefulness of Crispr/Cas9 genome editing 
to tag endogenous integrins for studies aimed at evaluating their expression, localization 
and function.  We were able to engineer an allele of the β4 integrin subunit with a tdTomato 
tag at its COOH-terminus that retained the properties of the wild-type allele and generate 
reporter cells harboring this tagged allele.  This resource, which enabled us to visualize β4 
in real-time, has distinct advantages over the use of immunofluorescence microscopy 
because it does not require fixation and is independent of issues related to antibody 
specificity.  Moreover, although the use of expression plasmids containing an epitope tag 
has proven useful for integrin studies, e.g., (225-228) , there are potential artifacts with this 
approach including the level of expression of the tagged integrin and competition with 
endogenous integrin that are obviated by the use of Crispr/Cas9 genome editing.    
The most exciting and informative data we obtained was from our analysis of β4 
expression and localization in response to a migratory stimulus (scratch wound).  Although 
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previous studies by our group and others had implicated β4 in migration, the ability to 
visualize endogenous integrin in real-time proved to be quite powerful.  This approach 
substantiated the dynamic nature of β4 during migration that we and others had observed 
based on more indirect approaches (235) but it also revealed novel insights.  Specifically, 
we note the relatively rapid increase in β4 expression that appeared to be coincident with 
the acquisition of motility in YAP-transformed reporter cells at the wound edge.  This 
finding provides visual evidence that supports previous work implicating β4 in migration 
(235).  It also underscores the notion that β4 expression and localization can change rapidly 
in response to alterations in the microenvironment.  This consideration should be a note of 
caution, for example, when interpreting data on the expression and localization of β4 in 
tumors based on the analysis of static images.  We were also struck by the extremely rapid 
migration of some of the YAP-transformed, β4-expressing cells, which was unexpected.  
These cells would not have been detected without their ability to be imaged in real-time, 
and their nature clearly merits further investigation.     
The β4 reporter cells that we have generated should be quite useful for studying 
other aspects of the contribution of this integrin to mammary gland biology and cancer.  
Comma-d1 cells are progenitor cells and capable of populating a mammary gland upon 
injection into the mammary fat pad of mice (247, 252, 253).   Long-term intravital 
microscopy (258) of the β4-tagged comma-d1 cells could provide novel insight into β4 
dynamics during mammary gland development.  The same approach could be used to 
visualize β4 during tumor formation in vivo using the YAP-transformed reporter cells.  
Given that β4 has been implicated in metastasis (234, 259, 260), the presence of the 
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tdTomato tag could facilitate the isolation and characterization of circulating tumor cells 
from mice harboring tumors generated by orthotopic injection of the YAP-transformed 
reporter cells.   
 
Materials and Methods 
Antibodies, flow cytometry and cell culture 
Immunoblotting antibodies were acquired as follows: Actin (4970S, Cell Signaling 
Technologies), β4 (ab29042, Abcam), red fluorescent protein that cross-reacts with 
tdTomato (ab62341, Abcam), Src (2108S, Cell Signaling Technologies), pY416 Src 
(2101S, Cell Signaling Technologies), α6 (provided by Dr. Anne Cress, University of 
Arizona) and Myc-tag (2278S, Cell Signaling Technologies).  β4 antibody 34611A 
(ab25254, Abcam) was used for flow cytometry.  Comma-d1 cells were provided by Dr. 
Nicholas Tonks (Cold Spring Harbor) and were cultured in Dulbecco's Modified Eagle 
Medium (DMEM)/F12 medium supplemented with 5% fetal bovine serum, insulin, 
epidermal growth factor (EGF) and HEPES.   
Constructs, sgRNAs and transfection 
We initially tested the cutting efficiency of 4 sgRNAs targeting the region of the 
last exon of mouse integrin β4 (sgRNA #1 = TGACCCAGGAATTCGTGACC; sgRNA 
#2 = CTGGGGCGCGGGGGAGGTTC; sgRNA #3 = 
GAGGAAGAAGGCGCTAGGAG; sgRNA #4 = GAGAGAGCCACTGGCCGTTA by 
cloning each sgRNA into lentiCrispr V2 vector.  Cells were subsequently infected with 
lentivirus carrying each sgRNA and puromycin selected (2 µg/mL) for 2 days.  TIDE 
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analysis (https://tide.nki.nl/) was performed to assess cutting efficiency of each sgRNA as 
well as flow cytometry to determine the effects on β4 surface abundance.  
After selecting the sgRNA #2 sequence, VectorBuilder 
(https://en.vectorbuilder.com/) was used to construct puromycin resistant sgRNA #2/Cas9 
plasmid (ID: VB180312-1135bvn) and the corresponding blasticidin resistant donor 
plasmid (ID: VB180312-1325zpa) to be transfected into comma-d1 cells. Approximately 
75,000 cells were seeded in six-well plates.  The next day cells were transfected with 800 
nanograms sgRNA/Cas9 plasmid and 500 nanograms circular donor plasmid using 
lipofectamine 3000 (Thermo Fisher Scientific) and processed for single-cell sorting 72 
hours later.  Hygromycin resistant Myc-5SA-YAP was purchased from Addgene (plasmid 
#33093) and was used to transform the β4 reporter comma-d1 cells.   
Polymerase chain reaction  
For qPCR, RNA was isolated using an RNA extraction kit (BS88133, Bio Basic 
Inc) and cDNAs were produced using qScript cDNA kit (#95047, Quantabio).  The qPCR 
master mix used was SYBR green (Applied Biosystems) and experiments were performed 
with three technical replicates and normalized to 18S.  The Massachusetts General 
Hospital/Harvard Medical School PrimerBank (http://pga.mgh.harvard.edu/primerbank/) 
was used to obtain qPCR primer sequences.   
To assess the correct insertion of tdTomato, genomic DNA was isolated using 
mammalian genomic DNA isolation kit (G1N70, Sigma) from comma-d1 cells that were 
grown from single cell clones.  Primers were designed to amplify the junction between β4 
genomic DNA and the left homology arm (Forward: 5’-AGGACCCCTCCAAATCAGTT-
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3’; Reverse: 5’-CAGGTCACCAGGTAGCCAAG-3’), the left homology arm and 
tdTomato (Forward: 5’- GAGCTGGGACCTGTACTCCA-3’; Reverse: 5’- 
GCTTCTTGTAATCGGGGATG-3’) and tdTomato and the right homology arm (Forward: 
5’- CCCGGCTACTACTACGTGGA-3’; Reverse: 5’- 
AGAACAAAAGGCTGGGGACT-3’).   
Mammosphere and soft agar assays 
UltraLow attachment 6 well plates were used for mammosphere experiments.  Cells 
were plated in DMEM/F12 medium supplemented with B27, EGF and fibroblast growth 
factor as previously described (63, 130).  Serial passaging was performed by pelleting and 
dissociating mammospheres with 0.05% Trypsin for 15 minutes at 37 degrees Celsius to 
obtain single cells, which were washed in 1X PBS, counted and re-plated in UltraLow 
attachment 6 well plates.  Soft agar colony formation was performed as previously 
described (66).   
Immunoblotting and co-immunoprecipitation  
Immunoblotting was accomplished by washing cells in 1X PBS and scraping them 
on ice in RIPA buffer with EDTA and EGTA (BP-115DG, Boston Bioproducts) 
supplemented with protease and phosphatase inhibitors (Roche, 04693132001).  Laemmli 
buffer (BP-111R, Boston Bioproducts) was added to each sample and the lysate was boiled 
and separated using sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE).  
NP-40 lysis buffer (BP-119, Boston Bioproducts) containing protease and phosphatase 
inhibitors (Roche, 04693132001) was used to extract protein for co-immunoprecipitation.  
Protein A agarose beads were added to the lysate and incubated for one hour at 4º Celsius 
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for pre-clearing.  Lysates were subsequently incubated with α6 antibody (555736, BD 
Biosciences) or IgG overnight at 4º Celsius.  The next morning lysates were incubated 
again with protein A agarose beads at 4º Celsius for one hour to pull down the protein 
complexes, which were separated using SDS-PAGE and immunoblotted for α6 and β4.        
Laminin attachment assay  
Cell culture dishes were coated with laminin-111 (23017015, Thermo Fisher 
Scientific) and blocked in 1% bovine serum album at for one hour at 37 degrees Celsius.  
Cells were trypsinized, plated on the laminin-111 coated plates and allowed to attach for 
one hour.  Subsequently, cells were lysed and immunoblotted for pY416 Src and Src or 
stained with crystal violet to measure the OD at 595 nm to determine adhesion.     
Scratch wound assay  
 Cells were seeded on six-well plates and grown to confluency.  A DeltaVision wide 
field deconvolution fluorescence microscope with temperature and CO2 control was used 
to capture images at 20X magnification of migrating cells at 15-minute intervals for 18 



































Fig. A.1.  Design, approach and validation for Crispr/Cas9-mediated integrin β4 
tagging.  (A) Comma-d1 cells expressing either a non-target sgRNA or one of four 
sgRNAs targeting the region of the last exon of mouse integrin β4 were processed for flow 
cytometry to determine the effects on β4 surface abundance.  (B) Genomic DNA was 
isolated from cells from (A) and was processed for TIDE analysis to quantify cutting 
efficiency of each sgRNA.  (C)  Depiction of the Crispr/Cas9 knock-in strategy and 
alterations that were engineered in the donor plasmid relative to the wild type β4 sequence.  
Mouse integrin β4 DNA sequence was downloaded from Ensembl genome browser 
(https://useast.ensembl.org/index.html).  Note that the sgRNA used corresponds to the 
complementary DNA strand shown.  (D) Comma-d1 cells were transfected with donor 
plasmid alone or donor plasmid and sgRNA #2/Cas9 plasmid and processed for flow 
cytometry to quantify tdTomato positive cells, which were subsequently processed for 
single-cell sorting. (E) Genomic DNA from clones described (D) was isolated and 
processed for PCR to determine the correct genomic insert of tdTomato.  (F) 
Immunoblotting was performed to confirm expression of tdTomato and the heterozygous 
tdTomato tagged β4 allele.  (G) Expression of tdTomato was quantified by flow cytometry 








Fig. A.2.  Integrin β4 reporter cells exhibit properties of parental cells.  (A) Analysis 
of β4 surface expression by flow cytometry of β4 reporter (blue line) and parental (red line) 
comma-d1 cells.  (B) Extracts of β4 reporter cells were immunoprecipitated using an 
integrin α6 Ab and then immunoblotted using an integrin β4 Ab.  Note that both the tagged- 
and untagged β4 alleles associate with α6.  (C) Cell culture dishes were coated with 
laminin-111 and β4 reporter and parental comma-d1 cells were allowed to attach for one 
hour.  Subsequently, crystal violet staining was performed to compare laminin-111 
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attachment.  (D) The cells in (C) were immunoblotted using a pY416 Src Ab to assess Src 
activation.  Densitometry was performed on these immunoblots using ImageJ (right graph).  
(E) Mammosphere forming ability was assessed in β4 reporter and parental comma-d1 
cells.  Dot plots (mean ± standard deviation) are representative of three independent 



































Fig. A.3.  Monitoring integrin β4 dynamics in non-transformed reporter cells in 
response to a scratch wound.  A scratch wound was introduced in β4 reporter comma-d1 
cells which were monitored for 18 hours.  Representative still images are shown.  Also 
seen Movies 1 and 2 for real-time immunofluorescence video microscopy.  Scale bar 



















Fig. A.4.  YAP transformation of integrin β4 reporter cells.  (A) Expression of Myc-
5SA-YAP or empty vector in β4 reporter comma-d1 cells was evaluated by 
immunoblotting.  (B) Expression of the YAP target genes ANKRD1 and Cyr61qPCR in 
both populations was quantified by qPCR.  Soft agar colony (C) and mammosphere 
formation (D) was assessed in the control and YAP-transformed β4 reporter comma-d1 
cells.  (E) β4 mRNA expression was quantified in the control and YAP-transformed cells 
by qPCR.  (F) Analysis of β4 surface expression by flow cytometry of β4 reporter cells 
expressing empty vector or 5SA-YAP.  Dot plots (mean ± standard deviation) are 
















Fig. A.5.  Monitoring integrin β4 dynamics in YAP-transformed reporter cells in 
response to a scratch wound.  A scratch wound was introduced in YAP-transformed β4 
reporter comma-d1 cells which were monitored for 18 hours.  Representative still images 
are shown.  Arrow indicates an example of a β4 positive cell that migrated more rapidly 
than neighboring cells.  Also see Movies 3-6 for real-time immunofluorescence video 















Movie 1.  18-hour movie of control β4 reporter comma-d1 cells in response to a scratch 
wound using a green differential interference contrast (DIC) background.  Scale bar 
represents 25 micrometers.    
Movie 2.  Movie 1 without a DIC background.  Scale bar represents 25 micrometers.     
Movie 3.  An 18-hour movie of YAP-transformed β4 reporter comma-d1 cells in response 
to a scratch wound using a green DIC background.  Scale bar represents 25 micrometers.     
Movie 4.  Movie 3 without a DIC background.  Scale bar represents 25 micrometers.     
Movie 5.  72-hour movie of YAP-transformed β4 reporter comma-d1 cells in response to 
a scratch wound using a green DIC background.  Scale bar represents 25 micrometers.     
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